#LCSM Transcript

Healthcare social media transcript of the #LCSM hashtag.
().
See #LCSM Influencers/Analytics.

Sign up for FREE Symplur Account and Get
  • Create Transcripts with Custom Dates
  • Get Custom Influencer Lists
  • 3x Hashtag Search Results
Sign Up Now
ProfileTweet
Brendon Stiles @BrendonStilesMD
Welcome to our #LCSM chat. Hoping that lots of people will join tonight! #lcsm
Faces of Lung Cancer @LungCancerFaces
RT @BrendonStilesMD: OK...drop what you are doing and at least say hello to #lcsm sometime in the next hour. Hoping we get a great showing…
Brendon Stiles @BrendonStilesMD
You can get more info at https://t.co/Lx9qF406C9 #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: OK...drop what you are doing and at least say hello to #lcsm sometime in the next hour. Hoping we get a great showing…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Welcome to our #LCSM chat. Hoping that lots of people will join tonight! #lcsm
Brendon Stiles @BrendonStilesMD
You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
Matthew Steliga MD @SteligaMD
Following along- looking forward to #LCSM tonight.
KC Dill @kasedill
Hello from Houston #LCSM
Brendon Stiles @BrendonStilesMD
To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twitter. #lcsm
Brendon Stiles @BrendonStilesMD
@SteligaMD Hi Matt! Thanks for joining. #lcsm
Peggy Dennis @peggyddennis
Hello from Denver #lcsm
Sara Whitlock @sjwhitlock
Hello from Ohio!!#LCSM
Brendon Stiles @BrendonStilesMD
@kasedill Thanks for joining! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
#LCSM Chat @lcsmchat
RT @SteligaMD: Following along- looking forward to #LCSM tonight. https://t.co/ArFY0MXkf4
Brendon Stiles @BrendonStilesMD
@sjwhitlock Oh, be still my heart! #lcsm
Janet Freeman-Daily @JFreemanDaily
Please join your #lungcancer tweeps for #lcsm chat NOW! We're talking about Recent Lung Cancer Conference Highlights. Don't miss it!
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twi…
Brendon Stiles @BrendonStilesMD
We'll get started in a few minutes -- please take a moment to introduce yourselves. #lcsm
Faces of Lung Cancer @LungCancerFaces
RT @JFreemanDaily: Please join your #lungcancer tweeps for #lcsm chat NOW! We're talking about Recent Lung Cancer Conference Highlights. Do…
Brendon Stiles @BrendonStilesMD
@peggyddennis Thanks Peggy! #lcsm
Brendon Stiles @BrendonStilesMD
I’m your moderator Brendon Stiles, a thoracic surgeon and patient advocate. And big believer in science and research. #lcsm
Henning Willers, MD @HenningWillers
Hi Brendon & all, Hello from Nantucket. Looking forward to listening and learning this evening. #lcsm
Benjamin King, MD @BenjaminKingMD1
Join me at #LCSM #tweetchat going on now to hear the latest and greatest from the world of #lungcancer screenings, diagnoses, treatments from multiple different perspectives #radonc
Janet Freeman-Daily @JFreemanDaily
Hi @BrendonStilesMD! Janet here in the lovely Pacific Northwest (but soon to be in Northern California for @don450sl's 10-year cancerversary party) #lcsm
Brendon Stiles @BrendonStilesMD
@HenningWillers My man! Thanks for joining and looking forward to your insight! #lcsm
Faces of Lung Cancer @LungCancerFaces
Deana here in sunny Los Angeles. I’ll be tweeting from the @lcsmchat account tonight. Let’s get this party started! #lcsm
Brendon Stiles @BrendonStilesMD
@BenjaminKingMD1 Thanks for joining!! #lcsm
Betsy @wildwestannie
Hello from Gloucester, MA #lcsm
Brendon Stiles @BrendonStilesMD
I would like to disclose conflicts – I chair @lcrf_org & have worked with @astrazeneca & @medtronic. My wife worked @pfizer and now @ppdCRO. #lcsm
Brendon Stiles @BrendonStilesMD
These don’t affect my opinions expressed tonight. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: We'll get started in a few minutes -- please take a moment to introduce yourselves. #lcsm
Frank Ingram, MD @Chucktowndoc
I’m Frank. Community pathologist in the Carolinas. Happy to be here! #lcsm
Brendon Stiles @BrendonStilesMD
In this week’s chat, we hope to explore new developments in lung cancer recently presented at major national meetings. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: I would like to disclose conflicts – I chair @lcrf_org & have worked with @astrazeneca & @medtronic. My wife worked @p
Brendon Stiles @BrendonStilesMD
@Chucktowndoc Awesome. Thanks for joining. Pathology is the key to lung cancer treatment. #lcsm
Deb Smith 🦋🌻🦉🐢🌿 @debsmithbeach
Deb here, on the chilly, damp NH Seacoast. #LCSM
Brendon Stiles @BrendonStilesMD
@wildwestannie Thanks for being with us. #lcsm
Brendon Stiles @BrendonStilesMD
These included the following hashtags: #AACR2019, #AATS2019, #ACR2019, #ASCO19, #ATS2019, and @IASLC meetings on Targeted Therapies and Small Cell Lung Cancer. #lcsm
Brendon Stiles @BrendonStilesMD
Lots of great organizations involved: @IASLC, @ASCO, @AACR, @AATSHQ, @STS, @RadiologyACR, @atscommunity #lcsm
KC Dill @kasedill
K.C. Dill, Houston stage 4 NSCLC 2//2015 Immunotherapy responder and advocate. #lcsm
Laura Greco @lgreco_ny
Laura here..ish from upstate New York. #lcsm
Brendon Stiles @BrendonStilesMD
@debsmithbeach Thanks for joining! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: These don’t affect my opinions expressed tonight. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: In this week’s chat, we hope to explore new developments in lung cancer recently presented at major national meetings.…
Brendon Stiles @BrendonStilesMD
This is a lot of ground to cover! A very daunting task. #lcsm
Benjamin King, MD @BenjaminKingMD1
Checking in from Los Angeles, I'm a radiation oncologist passionate about treating #lungcancer #advocacy and interdiscplinary care #lcsm
Kristin Ito @KAdvocate_LCAM
Kristin here from Denver, CO #lcsm
Brendon Stiles @BrendonStilesMD
@lgreco_ny Hi. I hope you are great. Looking forward to hearing your thoughts! #lcsm
Lung Cancer Sux @LungCancerSux
Hi! Glorianne from CT #lcsm
Alicia C. Staley @stales
RT @JFreemanDaily: Please join your #lungcancer tweeps for #lcsm chat NOW! We're talking about Recent Lung Cancer Conference Highlights. Do…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: These included the following hashtags: #AACR2019, #AATS2019, #ACR2019, #ASCO19, #ATS2019, and @IASLC meetings on Targ…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Lots of great organizations involved: @IASLC, @ASCO, @AACR, @AATSHQ, @STS, @RadiologyACR, @atscommunity #lcsm
Brendon Stiles @BrendonStilesMD
@KAdvocate_LCAM Awesome to have @iaslc team member in the house! #lcsm
Matthew Katz, MD @subatomicdoc
RT @subatomicdoc: @nejmcatalyst Co-design by patients, clinicians, caregivers, and relevant researchers/experts would work best. #hcldr #me
Brendon Stiles @BrendonStilesMD
@LungCancerSux Hooray! Thanks for joining us! #lcsm
Brendon Stiles @BrendonStilesMD
@BenjaminKingMD1 Thanks for joining! #lcsm
Dill Cipher 🥒 @Dill_Bot
RT @kasedill: K.C. Dill, Houston stage 4 NSCLC 2//2015 Immunotherapy responder and advocate. #lcsm
Brendon Stiles @BrendonStilesMD
And as always…#LungCancer has been a hot topic! #lcsm https://t.co/Mo1ifNloqA
Brendon Stiles @BrendonStilesMD
We will get started soon. First, a few reminders…#lcsm
Dr Mukesh Rulaniya @RulaniyaDr
RT @notahedge: @VivekSubbiah talking about the evolution of RET inhibitors at the BCM-MDACC Joint Drug Development Symposium @MDAndersonNew
Brendon Stiles @BrendonStilesMD
Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat #lcsm
Laura Greco @lgreco_ny
@BrendonStilesMD Wow! That is a little surprising to me. #lcsm
Brendon Stiles @BrendonStilesMD
If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: And as always…#LungCancer has been a hot topic! #lcsm https://t.co/Mo1ifNloqA
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: We will get started soon. First, a few reminders…#lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat #lcsm
Brendon Stiles @BrendonStilesMD
I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm
Brendon Stiles @BrendonStilesMD
We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm
Nathan A. Pennell MD, PhD @n8pennell
RT @IASLC: Abstract submission for our 2019 North America Conference on #LungCancer will close June 28th! Don't forget to submit your abst…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to fol…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm
Brendon Stiles @BrendonStilesMD
T1. How have the meetings changed over time and what is the best way for patients/advocates to understand what is important? #lcsm
Lung Cancer Sux @LungCancerSux
@sjwhitlock It still does...almost 10 years after dx! Hubby is stage 4 NED #lcsm
Audun Utengen @audvin
RT @subatomicdoc: @nejmcatalyst Co-design by patients, clinicians, caregivers, and relevant researchers/experts would work best. #hcldr #me
Brendon Stiles @BrendonStilesMD
T1. They have all gotten so BIG, that it can be challenging to stay on top of everything when actually there. #lcsm https://t.co/IxmVFHHTl5
Brendon Stiles @BrendonStilesMD
T1. Fortunately with #SoMe, Twitter in particular, what happens at meetings is now rapidly disseminated. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. How have the meetings changed over time and what is the best way for patients/advocates to understand what is imp…
Brendon Stiles @BrendonStilesMD
T1. What I love most is that it is not just media spin that gets rapidly disseminated, but expert opinion from multiple angles and perspectives. #lcsm https://t.co/GbVjwY8j8R
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. They have all gotten so BIG, that it can be challenging to stay on top of everything when actually there. #lcsm h…
Matthew Katz, MD @subatomicdoc
Good evening! Matt Katz, radiation oncologist in MA. I hope everyone is well tonight :-) #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Fortunately with #SoMe, Twitter in particular, what happens at meetings is now rapidly disseminated. #lcsm
Deborah Levesque @dtanz25
Patient here #lcsm
Brendon Stiles @BrendonStilesMD
T1. #SoMe also ensures that we are talking to each other across specialties, rather than just to our own individual societies. This helps us understand different interpretations of new data. #lcsm
Henning Willers, MD @HenningWillers
@BrendonStilesMD Even worse when you're not there! Twitter very useful to know whats going on! #lcsm
Frank Ingram, MD @Chucktowndoc
@BrendonStilesMD It’s true. Twitter is like an extra journal I read. A little heavy on editorials but still good! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. What I love most is that it is not just media spin that gets rapidly disseminated, but expert opinion from multip…
Peggy Dennis @peggyddennis
@BrendonStilesMD This is how I find what is important at the meetings...I follow you all on twitter. #lcsm
Brendon Stiles @BrendonStilesMD
T1. Of course, some organizations such as @IASLC, are already great platforms for multi-D collaboration. Others also working hard. #lcsm
Benjamin King, MD @BenjaminKingMD1
@BrendonStilesMD T1 Social media has allowed faster data dissemination. i can virtually "attend" meetings that time/resources previously prevented me from attending. also, it allows direct discourse between continents, specialties, even between patients and their team about care #lcsm
Sara Whitlock @sjwhitlock
T1: social media makes it possible for those of us not there to feel like we are keeping up at least a little! #LCSM
Brendon Stiles @BrendonStilesMD
T1. Many of the meetings have also made a focused effort to include patients/advocates and to tailor some sessions for them. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. #SoMe also ensures that we are talking to each other across specialties, rather than just to our own individual s…
Kristin Ito @KAdvocate_LCAM
@BrendonStilesMD T1. And exhausting! You really have to map out your schedule ahead of time. If the meeting organizer/organization helps to facilitate networking (approval of sharing emails to connect) - jump on the opportunity! #lcsm
#LCSM Chat @lcsmchat
RT @HenningWillers: @BrendonStilesMD Even worse when you're not there! Twitter very useful to know whats going on! #lcsm
#LCSM Chat @lcsmchat
RT @Chucktowndoc: @BrendonStilesMD It’s true. Twitter is like an extra journal I read. A little heavy on editorials but still good! #lcsm
#LCSM Chat @lcsmchat
RT @peggyddennis: @BrendonStilesMD This is how I find what is important at the meetings...I follow you all on twitter. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Of course, some organizations such as @IASLC, are already great platforms for multi-D collaboration. Others also…
#LCSM Chat @lcsmchat
RT @BenjaminKingMD1: @BrendonStilesMD T1 Social media has allowed faster data dissemination. i can virtually "attend" meetings that time/re…
Brendon Stiles @BrendonStilesMD
T1. This is great, because #PatientPerspective obviously matters a great deal. #lcsm
#LCSM Chat @lcsmchat
RT @sjwhitlock: T1: social media makes it possible for those of us not there to feel like we are keeping up at least a little! #LCSM
Nathan A. Pennell MD, PhD @n8pennell
T1. I think the social media coverage of meetings is vastly different than even 5 years ago. I can see presentations and commentary on studies from ESMO, Asian confs, and not even need to attend. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Many of the meetings have also made a focused effort to include patients/advocates and to tailor some sessions fo…
Laura Greco @lgreco_ny
T1 I don't have a personal point of reference BUT I saw recently that there has been a dip in patient social media activity at least in relation to ASCO. #lcsm
#LCSM Chat @lcsmchat
RT @KAdvocate_LCAM: @BrendonStilesMD T1. And exhausting! You really have to map out your schedule ahead of time. If the meeting organizer/o…
Matthew Katz, MD @subatomicdoc
RT @lgreco_ny: T1 I don't have a personal point of reference BUT I saw recently that there has been a dip in patient social media activity…
Brendon Stiles @BrendonStilesMD
Would be nice for meeting to make more of an effort to include physicians from multiple disciplines to give perspective. Like Twitter! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. This is great, because #PatientPerspective obviously matters a great deal. #lcsm
Matthew Katz, MD @subatomicdoc
RT @n8pennell: T1. I think the social media coverage of meetings is vastly different than even 5 years ago. I can see presentations and com…
#LCSM Chat @lcsmchat
RT @n8pennell: T1. I think the social media coverage of meetings is vastly different than even 5 years ago. I can see presentations and com…
Henning Willers, MD @HenningWillers
T1. There has been quite some talk on Twitter how expensive it is for patients and advocates to attend, and limited support for them #lcsm
#LCSM Chat @lcsmchat
RT @lgreco_ny: T1 I don't have a personal point of reference BUT I saw recently that there has been a dip in patient social media activity…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Would be nice for meeting to make more of an effort to include physicians from multiple disciplines to give perspectiv…
#LCSM Chat @lcsmchat
RT @HenningWillers: T1. There has been quite some talk on Twitter how expensive it is for patients and advocates to attend, and limited sup…
Matthew Katz, MD @subatomicdoc
RT @HenningWillers: T1. There has been quite some talk on Twitter how expensive it is for patients and advocates to attend, and limited sup…
Janet Freeman-Daily @JFreemanDaily
Amazingly #lcsm was the top trending hashtag for #ASCO19! #lungcancer has come a long way.
Brendon Stiles @BrendonStilesMD
@HenningWillers Thanks for bringing this up. I agree that we can do better supporting patients/advocates at these meetings. #lcsm
Brendon Stiles @BrendonStilesMD
RT @JFreemanDaily: Amazingly #lcsm was the top trending hashtag for #ASCO19! #lungcancer has come a long way. https://t.co/H14KVPp6ct
Brendon Stiles @BrendonStilesMD
@JFreemanDaily And this was even sort of a quiet year! #lcsm
Nathan A. Pennell MD, PhD @n8pennell
T1. I am concerned that meetings like ASCO are not tailored to deliver patient-friendly information. And perhaps the majority of doc-tweets are also directed at peers and not patients and advocates. How do we fix that? #lcsm
Mary Beth Miotto MD MPH @MAhealthforkids
RT @BenjaminKingMD1: @BrendonStilesMD T1 Social media has allowed faster data dissemination. i can virtually "attend" meetings that time/re…
Matthew Katz, MD @subatomicdoc
RT @JFreemanDaily: Amazingly #lcsm was the top trending hashtag for #ASCO19! #lungcancer has come a long way. https://t.co/H14KVPp6ct
#LCSM Chat @lcsmchat
RT @JFreemanDaily: Amazingly #lcsm was the top trending hashtag for #ASCO19! #lungcancer has come a long way. https://t.co/H14KVPp6ct
Brendon Stiles @BrendonStilesMD
T1. One important thing to remember: a lot of presentations haven’t been peer reviewed or disclosed all data. Easy to get caught up in hype of early studies that need more validation. #lcsm
Janet Freeman-Daily @JFreemanDaily
T1: 1/2 Increasingly, #lungcancer news from medical meetings is being shared on social media. Good way to find important info is to follow select hashtags on Twitter and search for blogs and videos of meeting highlights on vetted medical news sites. #LCSM #lcsm https://t.co/HHEke541PI
Timothy Craig Allen @TimAllenMDJD
RT @JFreemanDaily: Amazingly #lcsm was the top trending hashtag for #ASCO19! #lungcancer has come a long way. https://t.co/H14KVPp6ct
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @HenningWillers Thanks for bringing this up. I agree that we can do better supporting patients/advocates at these mee…
#LCSM Chat @lcsmchat
RT @n8pennell: T1. I am concerned that meetings like ASCO are not tailored to deliver patient-friendly information. And perhaps the majorit…
Henning Willers, MD @HenningWillers
@BrendonStilesMD @HenningWillers T1. how would one raise funds to provide financial support to patients/advocates to attend? #lcsm
Brendon Stiles @BrendonStilesMD
T1. We always have to be careful not to get caught up in the hype at meetings. Twitter is pretty good at giving some balance. #lcsm
Sara Whitlock @sjwhitlock
@n8pennell This is true. Even with my medical background I find it hard to wrap my head around so much of it #LCSM
Matthew Katz, MD @subatomicdoc
@n8pennell T1. I think it will take a structured, concerted effort to combat that tendency. It's easier to speak to peers than to the public or to any non-physician group imho #lcsm
Nathan A. Pennell MD, PhD @n8pennell
Despite this we had not one #LCSM person among the top influencers! I think this is because we had such broad spread of people tweeting this year, it was dozens and not just a few.
Laura Greco @lgreco_ny
RT @HenningWillers: @BrendonStilesMD @HenningWillers T1. how would one raise funds to provide financial support to patients/advocates to at…
Brendon Stiles @BrendonStilesMD
Moving to T2 soon. Immunotherapy. Have you heard of it? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. One important thing to remember: a lot of presentations haven’t been peer reviewed or disclosed all data. Easy t…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T1: 1/2 Increasingly, #lungcancer news from medical meetings is being shared on social media. Good way to find important…
Brendon Stiles @BrendonStilesMD
T2. What were the major findings regarding immunotherapy that were presented at the meetings? #lcsm
#LCSM Chat @lcsmchat
RT @HenningWillers: @BrendonStilesMD @HenningWillers T1. how would one raise funds to provide financial support to patients/advocates to at…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. We always have to be careful not to get caught up in the hype at meetings. Twitter is pretty good at giving some…
#LCSM Chat @lcsmchat
RT @sjwhitlock: @n8pennell This is true. Even with my medical background I find it hard to wrap my head around so much of it #LCSM
Janet Freeman-Daily @JFreemanDaily
@lgreco_ny I don't think that was a true dip in patient advocate #ASCO #SoMe activity. I think 2016 was just a year with an unusually high number of tweets. The other years are pretty even. #LCSM
#LCSM Chat @lcsmchat
RT @subatomicdoc: @n8pennell T1. I think it will take a structured, concerted effort to combat that tendency. It's easier to speak to peers…
#LCSM Chat @lcsmchat
RT @n8pennell: Despite this we had not one #LCSM person among the top influencers! I think this is because we had such broad spread of peop…
Brendon Stiles @BrendonStilesMD
T2. First of all, many patients are living A LOT longer! Data to follow. #lcsm
Matthew Katz, MD @subatomicdoc
RT @BrendonStilesMD: T2. What were the major findings regarding immunotherapy that were presented at the meetings? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Moving to T2 soon. Immunotherapy. Have you heard of it? #lcsm
Aki Alzubaidi @aki_alzubaidi
@BrendonStilesMD Totally agree with this @BrendonStilesMD #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. What were the major findings regarding immunotherapy that were presented at the meetings? #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @lgreco_ny I don't think that was a true dip in patient advocate #ASCO #SoMe activity. I think 2016 was just a year wit…
Laura Greco @lgreco_ny
@n8pennell I think it was truly a team effort! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. First of all, many patients are living A LOT longer! Data to follow. #lcsm
Robert S. Miller, MD @rsm2800
RT @n8pennell: Despite this we had not one #LCSM person among the top influencers! I think this is because we had such broad spread of peop…
Brendon Stiles @BrendonStilesMD
T2. At #AACR2019, a pooled analysis from 4 studies of nivolumab showed that 14% of previously treated patients were alive after 4 years. https://t.co/DNSoCzO90W #lcsm
Nathan A. Pennell MD, PhD @n8pennell
@subatomicdoc And to be honest I don't want to lose that peer to peer communication, it is a big part of why I like Twitter professionally. So we need to perhaps add patient-friendly content and not necessarily eliminate what we have. #lcsm
Benjamin King, MD @BenjaminKingMD1
T1. Agree. Data shared from meetings needs to be still viewed as such, just because abstracts are tweeted does not make it "published" in any way or form. even plenary session data needs to be vetted. #lcsm
Janet Freeman-Daily @JFreemanDaily
@n8pennell See what happens when I skip ASCO? :p #LCSM
Alicia C. Staley @stales
RT @subatomicdoc: @nejmcatalyst Co-design by patients, clinicians, caregivers, and relevant researchers/experts would work best. #hcldr #me
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. At #AACR2019, a pooled analysis from 4 studies of nivolumab showed that 14% of previously treated patients were a…
#LCSM Chat @lcsmchat
RT @n8pennell: @subatomicdoc And to be honest I don't want to lose that peer to peer communication, it is a big part of why I like Twitter…
Brendon Stiles @BrendonStilesMD
T2. Long term results from KEYNOTE-001 with pembrolizumab. 5 year OS of 23.2% in previously untreated patients! #lcsm https://t.co/PCIbKzS7Ov https://t.co/bTb28SVIfa
#LCSM Chat @lcsmchat
RT @BenjaminKingMD1: T1. Agree. Data shared from meetings needs to be still viewed as such, just because abstracts are tweeted does not mak…
Matthew Katz, MD @subatomicdoc
@n8pennell True, I agree. But it's a balancing act between communion with colleagues and building bridges between silos. #lcsm
Janet Freeman-Daily @JFreemanDaily
T1: 2/2 To find videos of top lung cancer docs talking about #lungcancer meeting highlights, Google keywords “thoracic cancer” or “lung cancer” and name of meeting. example ASCO 2019 LC highlights (scroll down to “thoracic cancers”: https://t.co/i1BjS4nuew #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Long term results from KEYNOTE-001 with pembrolizumab. 5 year OS of 23.2% in previously untreated patients! #lcs
Brendon Stiles @BrendonStilesMD
@sjwhitlock Getting there! #lcsm
Matthew Katz, MD @subatomicdoc
RT @BrendonStilesMD: T2. Long term results from KEYNOTE-001 with pembrolizumab. 5 year OS of 23.2% in previously untreated patients! #lcs
Brendon Stiles @BrendonStilesMD
T2. Results from the PACIFIC trial showed that stage III patients also live longer with durvalumab. #lcsm https://t.co/ikvG4VaFPv
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T1: 2/2 To find videos of top lung cancer docs talking about #lungcancer meeting highlights, Google keywords “thoracic c…
Kristin Ito @KAdvocate_LCAM
@n8pennell @lcsmchat @subatomicdoc Would it be possible/effective to work with your cancer center or medical center to do a type of "wrap up report" that could be shared online? #lcsm
Matthew Katz, MD @subatomicdoc
RT @JFreemanDaily: T1: 2/2 To find videos of top lung cancer docs talking about #lungcancer meeting highlights, Google keywords “thoracic c…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Results from the PACIFIC trial showed that stage III patients also live longer with durvalumab. #lcsm https://t.c…
Brendon Stiles @BrendonStilesMD
T2. Neoadjuvant studies were a big part of #ASCO19 and at #AATS2019: For example: NEOSTAR https://t.co/StB1mK09wd #lcsm https://t.co/p0brYe1bLZ
Matthew Katz, MD @subatomicdoc
RT @KAdvocate_LCAM: @n8pennell @lcsmchat @subatomicdoc Would it be possible/effective to work with your cancer center or medical center to…
Brendon Stiles @BrendonStilesMD
T2. NEOSTAR caused some concern over how many patients did not make it to surgery.#lcsm
Henning Willers, MD @HenningWillers
@BrendonStilesMD T2. PACIFIC really broke through the ceiling for stage III #lung cancer #lcsm
Brendon Stiles @BrendonStilesMD
T2. Also interesting point about pseudo-progression or “nodal immune flare” – PET findings may lead to overcall of progression. #lcsm https://t.co/Nyj3sVn81M
Matthew Katz, MD @subatomicdoc
RT @BrendonStilesMD: T2. Results from the PACIFIC trial showed that stage III patients also live longer with durvalumab. #lcsm https://t.c…
Brendon Stiles @BrendonStilesMD
RT @HenningWillers: @BrendonStilesMD T2. PACIFIC really broke through the ceiling for stage III #lung cancer #lcsm
Brendon Stiles @BrendonStilesMD
T2. LCMC3 study (sponsored in part by @lcrf_org) also presented findings of neoadjuvant atezolizumab study. 18% MPR. #lcsm https://t.co/wQeW3GT0uG
Henning Willers, MD @HenningWillers
@BrendonStilesMD T2. Neoadjuvant chemo + #immunotherapy has promise in stage II/III #lungcancer patients #lcsm
#LCSM Chat @lcsmchat
RT @KAdvocate_LCAM: @n8pennell @lcsmchat @subatomicdoc Would it be possible/effective to work with your cancer center or medical center to…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Neoadjuvant studies were a big part of #ASCO19 and at #AATS2019: For example: NEOSTAR https://t.co/StB1mK09wd #lc
Brendon Stiles @BrendonStilesMD
T2. We and others addressed safety of neoadjuvant IO at #AATS2019 #lcsm https://t.co/FCHNPGhUrP
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. NEOSTAR caused some concern over how many patients did not make it to surgery.#lcsm
Nathan A. Pennell MD, PhD @n8pennell
T2. The biggest news was the surprising % of patients treated with first-line pembrolizumab who survived 5 years, was I think 23% overall and 29% of high PDL1 expressers? I get the poster and abstract mixed up, I know the exact numbers changed. #lcsm
#LCSM Chat @lcsmchat
RT @HenningWillers: @BrendonStilesMD T2. PACIFIC really broke through the ceiling for stage III #lung cancer #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Also interesting point about pseudo-progression or “nodal immune flare” – PET findings may lead to overcall of pr…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. LCMC3 study (sponsored in part by @lcrf_org) also presented findings of neoadjuvant atezolizumab study. 18% MPR.…
Brendon Stiles @BrendonStilesMD
@HenningWillers Don't forget Neoadjuvant SBRT to IO! #lcsm
#LCSM Chat @lcsmchat
RT @HenningWillers: @BrendonStilesMD T2. Neoadjuvant chemo + #immunotherapy has promise in stage II/III #lungcancer patients #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. We and others addressed safety of neoadjuvant IO at #AATS2019 #lcsm https://t.co/FCHNPGhUrP
#LCSM Chat @lcsmchat
RT @n8pennell: T2. The biggest news was the surprising % of patients treated with first-line pembrolizumab who survived 5 years, was I thin…
Sara Whitlock @sjwhitlock
@BrendonStilesMD Saw a post from a patient just last week whose doc clearly didn’t understand this possibility and was ready to pull the plug on tx #LCSM
Brendon Stiles @BrendonStilesMD
T2. At #AACR2019 we got to see a report on the famous Cuban vaccine CIMAvax-EGF! Mostly just addressed safety with nivolumab. #lcsm https://t.co/ypG1PBBDjV
Matthew Katz, MD @subatomicdoc
RT @n8pennell: T2. The biggest news was the surprising % of patients treated with first-line pembrolizumab who survived 5 years, was I thin…
Benjamin King, MD @BenjaminKingMD1
T2. Data like these from #immunooncology shared are useful b/c often times it starts interdiscplinary dialogue. i can ask my #medonc colleagues if durvalumab or the next new IO is an option for our shared stage III pt who is finishing chemoRT. #lcsm
Brendon Stiles @BrendonStilesMD
T2. Also at #AACR2019, continued work on tumor mutational burden as a biomarker for response. Here with durvalumab. #lcsm https://t.co/mKTT9LWbcP https://t.co/E1bC908qpm
Angie Derrick @AngieBDerrick
RT @n8pennell: This is an emergency and must be addressed. Reports from academic centers that routinely test for molecular targets have giv…
Henning Willers, MD @HenningWillers
RT @BrendonStilesMD: T2. We and others addressed safety of neoadjuvant IO at #AATS2019 #lcsm https://t.co/FCHNPGhUrP
#LCSM Chat @lcsmchat
RT @sjwhitlock: @BrendonStilesMD Saw a post from a patient just last week whose doc clearly didn’t understand this possibility and was read…
Laura Greco @lgreco_ny
RT @n8pennell: T2. The biggest news was the surprising % of patients treated with first-line pembrolizumab who survived 5 years, was I thin…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. At #AACR2019 we got to see a report on the famous Cuban vaccine CIMAvax-EGF! Mostly just addressed safety with n…
#LCSM Chat @lcsmchat
RT @BenjaminKingMD1: T2. Data like these from #immunooncology shared are useful b/c often times it starts interdiscplinary dialogue. i can…
Nathan A. Pennell MD, PhD @n8pennell
To put this in context the 2-year OS in ECOG 1594 (published in 2002) was 12%. #lscm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Also at #AACR2019, continued work on tumor mutational burden as a biomarker for response. Here with durvalumab.…
Brendon Stiles @BrendonStilesMD
@BenjaminKingMD1 Great point! #lcsm
Brendon Stiles @BrendonStilesMD
RT @n8pennell: To put this in context the 2-year OS in ECOG 1594 (published in 2002) was 12%. #lscm https://t.co/l76sLtExnm
KC Dill @kasedill
RT @BrendonStilesMD: T2. At #AACR2019 we got to see a report on the famous Cuban vaccine CIMAvax-EGF! Mostly just addressed safety with n…
Gina @EAustin1969
I’m here lurkingas I fly #lcsm
Brendon Stiles @BrendonStilesMD
T2. Clearly, immunotherapy continues to be a game changer across the spectrum of lung cancer. Almost time to move to T3 - targeted therapy, our other pillar. #lcsm
Brendon Stiles @BrendonStilesMD
T3. What was presented at the meetings with regard to overcoming resistance to targeted therapy? #lcsm
Deb Smith 🦋🌻🦉🐢🌿 @debsmithbeach
RT @KAdvocate_LCAM: @n8pennell @lcsmchat @subatomicdoc Would it be possible/effective to work with your cancer center or medical center to…
Brendon Stiles @BrendonStilesMD
T3. Both intrinsic and acquired resistance remain as critical barriers for these patients. #lcsm https://t.co/dH4juunGzw
Benjamin King, MD @BenjaminKingMD1
@BrendonStilesMD @HenningWillers what #lungcancer trials are going on in this space? @CedarsSinai in #breastcancer #bcsm we have a neoadjuvant pembrolizumab RT study #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @JFreemanDaily: T1: 2/2 To find videos of top lung cancer docs talking about #lungcancer meeting highlights, Google keywords “thoracic c…
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T2. Results from the PACIFIC trial showed that stage III patients also live longer with durvalumab. #lcsm https://t.c…
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T1. One important thing to remember: a lot of presentations haven’t been peer reviewed or disclosed all data. Easy t…
KC Dill @kasedill
RT @JFreemanDaily: T1: 2/2 To find videos of top lung cancer docs talking about #lungcancer meeting highlights, Google keywords “thoracic c…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Clearly, immunotherapy continues to be a game changer across the spectrum of lung cancer. Almost time to move to…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. What was presented at the meetings with regard to overcoming resistance to targeted therapy? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Both intrinsic and acquired resistance remain as critical barriers for these patients. #lcsm https://t.co/dH4juu…
#LCSM Chat @lcsmchat
RT @BenjaminKingMD1: @BrendonStilesMD @HenningWillers what #lungcancer trials are going on in this space? @CedarsSinai in #breastcancer #bc
Matthew Katz, MD @subatomicdoc
RT @BrendonStilesMD: T3. Both intrinsic and acquired resistance remain as critical barriers for these patients. #lcsm https://t.co/dH4juu…
KC Dill @kasedill
RT @JFreemanDaily: Amazingly #lcsm was the top trending hashtag for #ASCO19! #lungcancer has come a long way. https://t.co/H14KVPp6ct
Brendon Stiles @BrendonStilesMD
T3. Sadly, resistance is a big part of the story for patients on targeted therapy. We have to do more to figure this out. #lcsm https://t.co/HRSoWWQlAX
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Sadly, resistance is a big part of the story for patients on targeted therapy. We have to do more to figure this…
Laura Greco @lgreco_ny
RT @BrendonStilesMD: T3. Sadly, resistance is a big part of the story for patients on targeted therapy. We have to do more to figure this…
Brendon Stiles @BrendonStilesMD
T3. Great session at #AACR19 w/ @LeciaSequist on new approaches to treating drug-resistant cancers, specifically EGFR driven tumors. #lcsm
Brendon Stiles @BrendonStilesMD
T3. Here is a blog describing: https://t.co/R3hCoL8dCJ #lcsm
Angie Derrick @AngieBDerrick
RT @HenningWillers: @BrendonStilesMD T2. Neoadjuvant chemo + #immunotherapy has promise in stage II/III #lungcancer patients #lcsm
Lois J Teston MD @LoisTeston
RT @BrendonStilesMD: T2. Long term results from KEYNOTE-001 with pembrolizumab. 5 year OS of 23.2% in previously untreated patients! #lcs
Brendon Stiles @BrendonStilesMD
T3. Tatton study from #AACR19 looked at strategy for EGFR resistance: adding savolitinib to osimertinib.#lcsm https://t.co/ZxuRlkI77u https://t.co/LnVEK6H0lR
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD T3: More research results are starting to get published about combination therapies to overcome targeted therapy acquired resistance, in #lungcancer, but we still have a long way to go. #LCSM
Brendon Stiles @BrendonStilesMD
T3. At #ASCO19, RELAY trial showed reduced disease progression by adding ramucirumab to erlotinib for patients with EGFR mutations. #lcsm https://t.co/EqC2C5RsIK
Matthew Katz, MD @subatomicdoc
@BrendonStilesMD T3. It's early in understanding how to integrate therapies, but in selected circumstances it may be worth consider focal therapy where tarteted therapy continues to work in most areas. #lcsm
Angie Derrick @AngieBDerrick
RT @JFreemanDaily: @BrendonStilesMD T3: More research results are starting to get published about combination therapies to overcome targete…
Janet Freeman-Daily @JFreemanDaily
.@BrendonStilesMD you are phenomenally well-prepared for this chat!@ Love all the content you're sharing. #lcsm
Brendon Stiles @BrendonStilesMD
@subatomicdoc Great point. #lcsm
Henning Willers, MD @HenningWillers
@BrendonStilesMD T3. Trend may be to start thinking about combination therapies including consolidation radiation before resistance #lcsm
Matthew Katz, MD @subatomicdoc
RT @JFreemanDaily: @BrendonStilesMD T3: More research results are starting to get published about combination therapies to overcome targete…
Brendon Stiles @BrendonStilesMD
@JFreemanDaily Hey! I take this responsibility seriously! #lcsm
Benjamin King, MD @BenjaminKingMD1
T3. How can new technologies e.g "liquid biopsies" allow for us to predict resistance/progession sooner than imaging or other modalites. isolating circulating tumor cells or circulating tumor DNA from blood tests could help prevent repeat biopsies that are invasive #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Great session at #AACR19 w/ @LeciaSequist on new approaches to treating drug-resistant cancers, specifically EGFR…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Here is a blog describing: https://t.co/R3hCoL8dCJ #lcsm
Aaron Andersen, MD @adandersen
@BrendonStilesMD With predominance of MET as a resistance mechanism what are thoughts on empiric use of MET inhibitor or combo with Osi? Repeat molecular testing? Hard to get tissue with heavy pre-treatment #lcsm #LungCancer
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Tatton study from #AACR19 looked at strategy for EGFR resistance: adding savolitinib to osimertinib.#lcsm https:…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @BrendonStilesMD T3: More research results are starting to get published about combination therapies to overcome targete…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. At #ASCO19, RELAY trial showed reduced disease progression by adding ramucirumab to erlotinib for patients with E…
#LCSM Chat @lcsmchat
RT @subatomicdoc: @BrendonStilesMD T3. It's early in understanding how to integrate therapies, but in selected circumstances it may be wort…
Lois J Teston MD @LoisTeston
RT @BrendonStilesMD: T3. Both intrinsic and acquired resistance remain as critical barriers for these patients. #lcsm https://t.co/dH4juu…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: .@BrendonStilesMD you are phenomenally well-prepared for this chat!@ Love all the content you're sharing. #lcsm
Brendon Stiles @BrendonStilesMD
@BenjaminKingMD1 Definitely the way forward. #lcsm
Matthew Katz, MD @subatomicdoc
@BrendonStilesMD It requires well-designed trials, but if targeted therapy works everywhere except one or two sites, should we switch therapy? Or consider surgery/radiation/ablation for those progressing sites? #lcsm
#LCSM Chat @lcsmchat
RT @HenningWillers: @BrendonStilesMD T3. Trend may be to start thinking about combination therapies including consolidation radiation befor…
#LCSM Chat @lcsmchat
RT @BenjaminKingMD1: T3. How can new technologies e.g "liquid biopsies" allow for us to predict resistance/progession sooner than imaging o…
#LCSM Chat @lcsmchat
RT @adandersen: @BrendonStilesMD With predominance of MET as a resistance mechanism what are thoughts on empiric use of MET inhibitor or co…
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD And we love you for it. #LCSM
#LCSM Chat @lcsmchat
RT @subatomicdoc: @BrendonStilesMD It requires well-designed trials, but if targeted therapy works everywhere except one or two sites, shou…
Lisa Briggs @livinglife82
If you are interested in learning about #clinicaltrials & how you can become more involved in #lungcancer #research, register for this ALTG consumer forum. July 17th in Sydney. #LCSM #Advocacy #Hope https://t.co/XeNvc1YUIU
Benjamin King, MD @BenjaminKingMD1
@JFreemanDaily @BrendonStilesMD 🤜(fist bump @BrendonStilesMD ) i'm learning clinical content while participating #lcsm
Angie Derrick @AngieBDerrick
RT @HenningWillers: @BrendonStilesMD T3. Trend may be to start thinking about combination therapies including consolidation radiation befor…
Aaron Andersen, MD @adandersen
@BenjaminKingMD1 Concern about low sensitivity? What about isolated CNS progression? #lcsm #lepto
Brendon Stiles @BrendonStilesMD
T3. Making progress. Just have to make it to next drug. Or make the next drug! #lcsm https://t.co/tVORqGo8ma
#LCSM Chat @lcsmchat
RT @BenjaminKingMD1: @JFreemanDaily @BrendonStilesMD 🤜(fist bump @BrendonStilesMD ) i'm learning clinical content while participating #lcsm
Sara Whitlock @sjwhitlock
@subatomicdoc @BrendonStilesMD As a patient doing well on targeted therapy, I would vote for spot treating the trouble areas. #lcsm
Brendon Stiles @BrendonStilesMD
T3. The obvious big frontier is figuring out how to integrate immune approaches with targeted therapy. That would be the #BigWin #lcsm
IASLC @IASLC
IASLC #SCLC19 Tweet II - Organized Julie George, @TGOliver2, J.T. Poirier and @teekayowo, #SCLC19 was a multidisciplinary event that highlighted SCLC-specific advances in a wide-variety of disciplines: including pathology, science, patient advocacy and many others. #LCSM
IASLC @IASLC
IASLC #SCLC19 Tweet I - The scientific community is striving to understand #SCLC – utilizing a variety of unique approaches such as genomics, transcriptomics, metabolomics and new mouse models. #LCSM
Kristin Ito @KAdvocate_LCAM
@BenjaminKingMD1 @lcsmchat @JFreemanDaily @BrendonStilesMD Ditto! This is why the LCSM chat is so important! #lcsm
Michele McKenzie @MColvinMcKenzie
RT @JFreemanDaily: T1: 2/2 To find videos of top lung cancer docs talking about #lungcancer meeting highlights, Google keywords “thoracic c…
Brendon Stiles @BrendonStilesMD
@sjwhitlock @subatomicdoc Any time my darling! Just call me! #lcsm
Aaron Andersen, MD @adandersen
Great option to prolong first-gen #tki? #LCSM
Brendon Stiles @BrendonStilesMD
T4 coming! New stuff! #lcsm
#LCSM Chat @lcsmchat
RT @adandersen: @BenjaminKingMD1 Concern about low sensitivity? What about isolated CNS progression? #lcsm #lepto
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Making progress. Just have to make it to next drug. Or make the next drug! #lcsm https://t.co/tVORqGo8ma
#LCSM Chat @lcsmchat
RT @sjwhitlock: @subatomicdoc @BrendonStilesMD As a patient doing well on targeted therapy, I would vote for spot treating the trouble area…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. The obvious big frontier is figuring out how to integrate immune approaches with targeted therapy. That would be…
Brendon Stiles @BrendonStilesMD
T4. Has there been progress in finding new therapeutic targets and in bringing new drugs to the clinic? #lcsm
Brendon Stiles @BrendonStilesMD
T4. Here is a good overview from #AACR2019 #lcsm https://t.co/qMFyCZYrqn
Benjamin King, MD @BenjaminKingMD1
@sjwhitlock @subatomicdoc @BrendonStilesMD thank you for your input @sjwhitlock! patient input is essential to decision-making, especially where there are no "right" answers. decisions = weighing costs and benefits but those are subjective and depend on perspective #PatientCenteredCare #lcsm
Brendon Stiles @BrendonStilesMD
T4. The ARROW study in which BLU-667, a selective RET inhibitor, demonstrated clinical activity and tolerability in patients with advanced RET fusion–positive non–small cell lung cancer #lcsm https://t.co/Va9g2AtSED
KC Dill @kasedill
@BrendonStilesMD Yes is Nivolumab old news is there something better?#LCSM
Sara Whitlock @sjwhitlock
@BrendonStilesMD @subatomicdoc You know you would be the first one I’d call!#LCSM
Kim Moran-MacIntosh 🇨🇦 @Kamacintosh
RT @BrendonStilesMD: T3. Making progress. Just have to make it to next drug. Or make the next drug! #lcsm https://t.co/tVORqGo8ma
Gary L. Thompson @garyleethompson
Joining #lcsm in honor of a friend who was just diagnosed with Stage 4 #lungcancer Early 40s. Non-smoker. Still in shock.
Matthew Katz, MD @subatomicdoc
RT @BrendonStilesMD: T4. Has there been progress in finding new therapeutic targets and in bringing new drugs to the clinic? #lcsm
Brendon Stiles @BrendonStilesMD
Lots of stuff happening in the RET space! #lcsm https://t.co/PF0L955kzh
Laura Greco @lgreco_ny
@JFreemanDaily Perhaps, but why is it flat when docs' use is exploding? I think we should be growing as well. #lcsm
#LCSM Chat @lcsmchat
RT @IASLC: IASLC #SCLC19 Tweet II - Organized Julie George, @TGOliver2, J.T. Poirier and @teekayowo, #SCLC19 was a multidisciplinary event…
#LCSM Chat @lcsmchat
RT @IASLC: IASLC #SCLC19 Tweet I - The scientific community is striving to understand #SCLC – utilizing a variety of unique approaches such…
#LCSM Chat @lcsmchat
RT @KAdvocate_LCAM: @BenjaminKingMD1 @lcsmchat @JFreemanDaily @BrendonStilesMD Ditto! This is why the LCSM chat is so important! #lcsm
#LCSM Chat @lcsmchat
RT @adandersen: Great option to prolong first-gen #tki? #LCSM https://t.co/i9LiG8ySHM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4 coming! New stuff! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Has there been progress in finding new therapeutic targets and in bringing new drugs to the clinic? #lcsm
Brendon Stiles @BrendonStilesMD
T4. Getting closer on cMet with strong drug options emerging: #lcsm https://t.co/sFBFy9xVmB
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Here is a good overview from #AACR2019 #lcsm https://t.co/qMFyCZYrqn
KC Dill @kasedill
@garyleethompson Welcome, there is hope and expertise here #LCSM.
#LCSM Chat @lcsmchat
RT @BenjaminKingMD1: @sjwhitlock @subatomicdoc @BrendonStilesMD thank you for your input @sjwhitlock! patient input is essential to decisio…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. The ARROW study in which BLU-667, a selective RET inhibitor, demonstrated clinical activity and tolerability in p…
#LCSM Chat @lcsmchat
RT @kasedill: @BrendonStilesMD Yes is Nivolumab old news is there something better?#LCSM
Sara Whitlock @sjwhitlock
@BrendonStilesMD Hooray!!!#lcsm #retgirl
Brendon Stiles @BrendonStilesMD
T4. Lots of excitement about a drug targeting KRAS – long thought to be “undruggable”. #lcsm https://t.co/XQjmkTnsEc https://t.co/KPQXqktejF
#LCSM Chat @lcsmchat
RT @garyleethompson: Joining #lcsm in honor of a friend who was just diagnosed with Stage 4 #lungcancer Early 40s. Non-smoker. Still in sho…
Peggy Dennis @peggyddennis
T4 Exciting new research and clinical's involving EGFR and ERBB (HER) mutations. Would like to see more for this population. #lcsm
Kim Moran-MacIntosh 🇨🇦 @Kamacintosh
RT @BrendonStilesMD: T3. Both intrinsic and acquired resistance remain as critical barriers for these patients. #lcsm https://t.co/dH4juu…
Brendon Stiles @BrendonStilesMD
@lgreco_ny @JFreemanDaily Without a doubt! #lcsm
Mike Thompson, MD, PhD, FASCO @mtmdphd
RT @BrendonStilesMD: T3. Sadly, resistance is a big part of the story for patients on targeted therapy. We have to do more to figure this…
IASLC @IASLC
IASLC #SCLC19 Tweet III - @MontessaLee, who was diagnosed with #SCLC in 2006, gave a special address to #SCLC19 attendees. Montessa recovered after being treated with chemotherapy and radiation. #LCSM
Brendon Stiles @BrendonStilesMD
T4. Still early, but exciting data with KRAS. And lots of other targets well along. #lcsm
Sara Whitlock @sjwhitlock
@BrendonStilesMD A small but mighty group!!#LCSM
Janet Freeman-Daily @JFreemanDaily
RT @livinglife82: If you are interested in learning about #clinicaltrials & how you can become more involved in #lungcancer #research, regi…
Brendon Stiles @BrendonStilesMD
T4. Also exciting stuff happening with targets in small cell cancer. @iaslc had a dedicated small cell meeting. We need to do MUCH better for these patients. #lcsm
#LCSM Chat @lcsmchat
@garyleethompson Tell your friend we’re here for him/her. Lung cancer in young never-smokers is not uncommon. We can provide info, resources and community. #lcsm
Mike Thompson, MD, PhD, FASCO @mtmdphd
RT @BrendonStilesMD: T4. Getting closer on cMet with strong drug options emerging: #lcsm https://t.co/sFBFy9xVmB
Sara Whitlock @sjwhitlock
So exciting for a lot of LC patients👏🏻👏🏻#LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Lots of stuff happening in the RET space! #lcsm https://t.co/PF0L955kzh
Brendon Stiles @BrendonStilesMD
T5 coming up! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Getting closer on cMet with strong drug options emerging: #lcsm https://t.co/sFBFy9xVmB
Brendon Stiles @BrendonStilesMD
T5. What is happening with regard to screening, early diagnosis, and treatment of early stage lung cancer? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Lots of excitement about a drug targeting KRAS – long thought to be “undruggable”. #lcsm https://t.co/XQjmkTnsEc…
#LCSM Chat @lcsmchat
RT @peggyddennis: T4 Exciting new research and clinical's involving EGFR and ERBB (HER) mutations. Would like to see more for this populati…
#LCSM Chat @lcsmchat
RT @IASLC: IASLC #SCLC19 Tweet III - @MontessaLee, who was diagnosed with #SCLC in 2006, gave a special address to #SCLC19 attendees. Monte…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Still early, but exciting data with KRAS. And lots of other targets well along. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Also exciting stuff happening with targets in small cell cancer. @iaslc had a dedicated small cell meeting. We…
Ryo. Oncology @OncologyRyo
RT @StephenVLiu: #CIOT19 Opening lecture by @peters_solange - two @myESMO presidents on stage together! Reviewing tremendous advances in IO…
Kristin Ito @KAdvocate_LCAM
@IASLC @MontessaLee It was wonderful to have @MontessaLee there to share her story and encourage more research! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. What is happening with regard to screening, early diagnosis, and treatment of early stage lung cancer? #lcsm
Brendon Stiles @BrendonStilesMD
T5. Vinay Prasad announced at all major meetings that he now supports lung cancer screening. Not really! #lcsm
KC Dill @kasedill
RT @lcsmchat: @garyleethompson Tell your friend we’re here for him/her. Lung cancer in young never-smokers is not uncommon. We can provide…
Brendon Stiles @BrendonStilesMD
T5. An #AACR2019 “Dream Team” is working on early detection and interception of lung cancer. https://t.co/TodhLLrm7A #lcsm
Matthew Katz, MD @subatomicdoc
RT @BrendonStilesMD: T4. Also exciting stuff happening with targets in small cell cancer. @iaslc had a dedicated small cell meeting. We…
Flemming Rasmussen @fgrazz
@BrendonStilesMD T4 - Progress? Targets am not certain but have seen seed funding and interest in supporting different paths #lcsm
Janet Freeman-Daily @JFreemanDaily
T4: Oncology meetings are including more on patient experience. One poster at #ASCO19 found broadening clinical trial eligibility (per recommendations from @ASCO and @CancerResrch) would nearly double number of patients eligible for NSCLC trials. https://t.co/aYxSrglDK9 #LCSM
Sharon White @whitesl365
More amazing Cancer research. @cancerNSW @abcnews @GarvanInstitute @ResAustralia @CCNSWResearch @WorldwideCancer @PeterMacCC
Laura Greco @lgreco_ny
@BrendonStilesMD @IASLC That's overdue. I have often wondered why we don't do symposia with all stakeholders by targetable mutation.... let's really drill down on each subset! #lcsm
Brendon Stiles @BrendonStilesMD
T5. Kudos to #ASCO19 for featuring presentations on access to care and early diagnosis. We know both things are critical. #lcsm https://t.co/QN8WyKVKWA
Sara Whitlock @sjwhitlock
@BrendonStilesMD Within the small group I work with I’m always preaching screening and get SO MUCH PUSHBACK! Maddening #LCSM
Gary L. Thompson @garyleethompson
@sjwhitlock Thank you! I have participated in #BCSM for years having lost my wife to #Breastcancer on 10.21.2014 Communities like #lcsm are so vital!
Brendon Stiles @BrendonStilesMD
T5. Interesting study from #ASCO2019 on the role insurance plays in early diagnosis and time to treatment. It was for ovarian cancer, but I suspect similarities exist with #LungCancer #lcsm. https://t.co/ilh1ysuwut
#LCSM Chat @lcsmchat
Lulz #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. An #AACR2019 “Dream Team” is working on early detection and interception of lung cancer. https://t.co/TodhLLrm7A…
#LCSM Chat @lcsmchat
RT @fgrazz: @BrendonStilesMD T4 - Progress? Targets am not certain but have seen seed funding and interest in supporting different paths #l
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T4: Oncology meetings are including more on patient experience. One poster at #ASCO19 found broadening clinical trial el…
Brendon Stiles @BrendonStilesMD
T5. Hopefully, radiomics and machine learning will continue to help radiologists from @RadiologyACR classify nodules to help minimize concerns over “false positives”. #lcsm
#LCSM Chat @lcsmchat
RT @lgreco_ny: @BrendonStilesMD @IASLC That's overdue. I have often wondered why we don't do symposia with all stakeholders by targetable…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Kudos to #ASCO19 for featuring presentations on access to care and early diagnosis. We know both things are crit…
Angie Derrick @AngieBDerrick
RT @BrendonStilesMD: T4. Also exciting stuff happening with targets in small cell cancer. @iaslc had a dedicated small cell meeting. We…
#LCSM Chat @lcsmchat
RT @sjwhitlock: @BrendonStilesMD Within the small group I work with I’m always preaching screening and get SO MUCH PUSHBACK! Maddening #LC
Kristin Ito @KAdvocate_LCAM
@lgreco_ny @BrendonStilesMD @IASLC Great idea! #lcsm
Laura Greco @lgreco_ny
RT @JFreemanDaily: T4: Oncology meetings are including more on patient experience. One poster at #ASCO19 found broadening clinical trial el…
Brendon Stiles @BrendonStilesMD
T5. Good session at #ACR2019 regarding radiologists taking the lead for lung cancer screening. #lcsm
IASLC @IASLC
IASLC #SCLC19 TV - These included one by Dr. Lovly on using blood to look for tumor DNA, which can monitor the response of #SCLC tumors to therapy, and one by Dr. Johnson, which covered how #SCLC can be divided into subtypes on the molecular characteristics of the tumor. #LCSM
IASLC @IASLC
IASLC #SCLC19 Tweet VI - Finally, there was a presentation by Dr. Julien Sage on understanding how #SCLC metastasizes by studying the way the cells look and change their shape. #LCSM #LungCancer
#LCSM Chat @lcsmchat
@garyleethompson @sjwhitlock Very sorry for the loss of your beloved wife. #stage4needsmore #lcsm
Angie Derrick @AngieBDerrick
RT @BrendonStilesMD: T5. An #AACR2019 “Dream Team” is working on early detection and interception of lung cancer. https://t.co/TodhLLrm7A…
#LCSM Chat @lcsmchat
RT @garyleethompson: @sjwhitlock Thank you! I have participated in #BCSM for years having lost my wife to #Breastcancer on 10.21.2014 Commu…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Interesting study from #ASCO2019 on the role insurance plays in early diagnosis and time to treatment. It was fo…
Brendon Stiles @BrendonStilesMD
T5. Nice study from @DrRianCharles on improving screening rates and retention in high risk rural populations. 2.2% incidence of lung cancer of which 68% had early stage disease. #lcsm https://t.co/pcaPOWwljr
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Hopefully, radiomics and machine learning will continue to help radiologists from @RadiologyACR classify nodules…
Janet Freeman-Daily @JFreemanDaily
@lgreco_ny I think patient advocates initially try to tweet everything at #ASCO, but after a year or two are more selective in what they tweet. Hard to follow every slide in presentations when trying to condense findings into 280 characters! #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Good session at #ACR2019 regarding radiologists taking the lead for lung cancer screening. #lcsm
#LCSM Chat @lcsmchat
RT @IASLC: IASLC #SCLC19 TV - These included one by Dr. Lovly on using blood to look for tumor DNA, which can monitor the response of #SCLC
Flemming Rasmussen @fgrazz
@fgrazz @BrendonStilesMD T4 - Not anywhere near clinical /bedside stage though...its a good start to assess viability in new spaces #lcsm
#LCSM Chat @lcsmchat
RT @IASLC: IASLC #SCLC19 Tweet VI - Finally, there was a presentation by Dr. Julien Sage on understanding how #SCLC metastasizes by studyin…
Brendon Stiles @BrendonStilesMD
T5. Accurate staging is key and increasingly be done with bronchoscopy/EBUS. Surgeons (@wc_hanna) working hard to confirm accuracy. #lcsm https://t.co/uyEKzI5Add
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Nice study from @DrRianCharles on improving screening rates and retention in high risk rural populations. 2.2% i…
Matthew Katz, MD @subatomicdoc
RT @BrendonStilesMD: T5. Nice study from @DrRianCharles on improving screening rates and retention in high risk rural populations. 2.2% i…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @lgreco_ny I think patient advocates initially try to tweet everything at #ASCO, but after a year or two are more select…
#LCSM Chat @lcsmchat
RT @fgrazz: @fgrazz @BrendonStilesMD T4 - Not anywhere near clinical /bedside stage though...its a good start to assess viability in new sp…
Brendon Stiles @BrendonStilesMD
T5. Surgeons also still trying to figure out how to manage “part-solid” nodules. They seem to be oncologically distinct from solid nodules. Great review from JCOG0201 dataset. #lcsm https://t.co/Ny8aNW7QWT
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Accurate staging is key and increasingly be done with bronchoscopy/EBUS. Surgeons (@wc_hanna) working hard to co…
Brendon Stiles @BrendonStilesMD
T5. Lots of research being done in area of endobronchial image guided techniques to improve diagnosis of nodules, but also potentially for ablative treatment of tumors. #lcsm https://t.co/n1lZaY7TlM
Henning Willers, MD @HenningWillers
RT @BrendonStilesMD: T5. Surgeons also still trying to figure out how to manage “part-solid” nodules. They seem to be oncologically disti…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Surgeons also still trying to figure out how to manage “part-solid” nodules. They seem to be oncologically disti…
KC Dill @kasedill
This! #lcsm
Brendon Stiles @BrendonStilesMD
T5. Surgeons are also increasingly factoring in histology and molecular features to help determine extent of resection. #PathologyMatters #lcsm
Brendon Stiles @BrendonStilesMD
T5. Surgeons and #Radonc know about concept of STAS – spread through air spaces. Increasingly recognized on histology and may predict local recurrence after limited resection or SBRT. #lcsm
Gary L. Thompson @garyleethompson
@lcsmchat @sjwhitlock Thank you. ❤️❤️ 25 years of marriage. Three amazing kids that are a reflection of our love. #lcsm
Brendon Stiles @BrendonStilesMD
T5. Here is an abstract about STAS from #AATS2019: #lcsm https://t.co/Nqd0noaDMn
Henning Willers, MD @HenningWillers
RT @BrendonStilesMD: T5. An #AACR2019 “Dream Team” is working on early detection and interception of lung cancer. https://t.co/TodhLLrm7A…
Angie Derrick @AngieBDerrick
RT @BrendonStilesMD: T5. Nice study from @DrRianCharles on improving screening rates and retention in high risk rural populations. 2.2% i…
Matthew Katz, MD @subatomicdoc
RT @BrendonStilesMD: T5. Surgeons are also increasingly factoring in histology and molecular features to help determine extent of resectio…
Brendon Stiles @BrendonStilesMD
T5. Presentations regarding safety of surgery after IO were featured at #AATS2019: after atezolizumab (LCMC) and durvalumab (our group) #lcsm https://t.co/YReVZ7cGHW
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Lots of research being done in area of endobronchial image guided techniques to improve diagnosis of nodules, but…
Henning Willers, MD @HenningWillers
RT @BrendonStilesMD: T5. Surgeons and #Radonc know about concept of STAS – spread through air spaces. Increasingly recognized on histolog…
Eon @eonhealth
We are working in these areas to pioneer lung cancer screening programs AND incidental lung nodule programs, less patients falling through the cracks. Wins for patients and providers #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Surgeons are also increasingly factoring in histology and molecular features to help determine extent of resectio…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Surgeons and #Radonc know about concept of STAS – spread through air spaces. Increasingly recognized on histolog…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Here is an abstract about STAS from #AATS2019: #lcsm https://t.co/Nqd0noaDMn
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Presentations regarding safety of surgery after IO were featured at #AATS2019: after atezolizumab (LCMC) and durva…
Brendon Stiles @BrendonStilesMD
Almost time to wind the chat down. This has been an incredible discussion. #lcsm
Brendon Stiles @BrendonStilesMD
Please share your closing thoughts! #lcsm
Henning Willers, MD @HenningWillers
@BrendonStilesMD How well can STAS be diagnosed from a core biopsy (as opposed to wedge)? #LCSM
Aki Alzubaidi @aki_alzubaidi
Track every patient! #lcsm
Peggy Dennis @peggyddennis
Closing thoughts...I have homework! Thanks for all the great info. #lcsm
Brendon Stiles @BrendonStilesMD
@HenningWillers Not very but solid or micropapillary subtypes might predict. #lcsm
nel cuevas muñoz @MunozNel
RT @JCO_ASCO: Neoadjuvant erlotinib for stage IIA-N2 EGFR-mutant non-small cell lung cancer https://t.co/j0uY8gDsmA #lcsm https://t.co/5a4P…
Brendon Stiles @BrendonStilesMD
Thanks to all of the #lcsm community who joined. Great turnout! #lcsm
Brendon Stiles @BrendonStilesMD
RT @aki_alzubaidi: Track every patient! #lcsm
Carla @VolGirl_4Life
RT @BrendonStilesMD: T5. Kudos to #ASCO19 for featuring presentations on access to care and early diagnosis. We know both things are crit…
#LCSM Chat @lcsmchat
Thank you to our moderator @BrendonStilesMD for another wonderful chat! #LCSM
KC Dill @kasedill
@BrendonStilesMD I’m going visit the recap. What a fast furious informative chat. Lots to take in and study. Thank you so much for moderating. #Lcsm.
Kristin Ito @KAdvocate_LCAM
@BrendonStilesMD There are MANY more meetings to come in the remainder of 2019! Continue to share the knowledge and advocate on! #LCSM
Brendon Stiles @BrendonStilesMD
#Research moves the needle and saves lives. We have to support it. #lcsm
Benjamin King, MD @BenjaminKingMD1
T5. @Dr_RayMak @DanaFarber doing excellent work on functional imaging studies/MRI, genomic predictors for response to radiation for #LungCancer https://t.co/lLsig5OKxP #lcsm
Janet Freeman-Daily @JFreemanDaily
I am encouraged by progress in so many areas of #lungcancer research--different stages, different biomarkers, different spread, yet increasing survival. Looking forward to the 2020 SEER 5-year survival numbers for LC! #LCSM
KC Dill @kasedill
RT @BrendonStilesMD: #Research moves the needle and saves lives. We have to support it. #lcsm
Sara Whitlock @sjwhitlock
8.5 years in with stageIV LC I continue to have so much hope for all our futures! Thanks to all. Docs and advocates. We all have our part to play!#lcsm
Kristin Ito @KAdvocate_LCAM
YES! #LCSM #LCAM
Brendon Stiles @BrendonStilesMD
Thanks to everyone for participating! I love the #lcsm community and learn from you all every day.
KC Dill @kasedill
@JFreemanDaily Me too Janet! #lcsm
Brendon Stiles @BrendonStilesMD
Hope everyone will join us at @iaslc #WCLC in Barcelona in September! #lcsm
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD Closing thoughts: Thanks to the amazing @BrendonStilesMD for his solid preparation and sheer number of tweets tonight! Great chat. Proud to be part of the #LCSM community.
Brendon Stiles @BrendonStilesMD
@kasedill I told you this was a lot to cover! I will have to go through the details too! #lcsm
Faces of Lung Cancer @LungCancerFaces
Hope to see lots of #LungCancerPeople in Winters, CA this weekend at @don450sl’s 10 year LC survival shindig! See you soon @lysabee @paulalv @JFreemanDaily @lgreco_ny @AboutLungCancer @chrisdraft & everyone else! #lcsm
Henning Willers, MD @HenningWillers
@BrendonStilesMD Spain is tempting but #radonc ASTRO meeting in Chicago in September is also nice ... you'll here about it on Twitter! #lcsm
Benjamin King, MD @BenjaminKingMD1
Closing thoughts: so much promise, new class of medications (#immunooncology), but still far to go to treat and cure patients with #lungcancer. some of the best minds are hard at work like @BrendonStilesMD @DrewMoghanaki #lcsm
Brendon Stiles @BrendonStilesMD
@JFreemanDaily You gave me a big task! Just do as I am told. Hopefully shared some useful highlights that people can reflect upon. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Thanks to all of the #lcsm community who joined. Great turnout! #lcsm
Sarah Hayes @drsarahhayes
RT @JTOonline: In the latest JTO Editor’s Choice, we present a study conducted by Negrao and his colleagues regarding predictive biomarkers…
#LCSM Chat @lcsmchat
RT @KAdvocate_LCAM: @BrendonStilesMD There are MANY more meetings to come in the remainder of 2019! Continue to share the knowledge and adv…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: #Research moves the needle and saves lives. We have to support it. #lcsm
#LCSM Chat @lcsmchat
RT @BenjaminKingMD1: T5. @Dr_RayMak @DanaFarber doing excellent work on functional imaging studies/MRI, genomic predictors for response to…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: I am encouraged by progress in so many areas of #lungcancer research--different stages, different biomarkers, different…
#LCSM Chat @lcsmchat
RT @sjwhitlock: 8.5 years in with stageIV LC I continue to have so much hope for all our futures! Thanks to all. Docs and advocates. We al…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Thanks to everyone for participating! I love the #lcsm community and learn from you all every day.
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Hope everyone will join us at @iaslc #WCLC in Barcelona in September! #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @BrendonStilesMD Closing thoughts: Thanks to the amazing @BrendonStilesMD for his solid preparation and sheer number of…
Brendon Stiles @BrendonStilesMD
What we need is a full on #lcsm retreat to discuss our path forward, how we should shape our social media strategy, and where we should focus resources. We are a powerful group!
#LCSM Chat @lcsmchat
RT @LungCancerFaces: Hope to see lots of #LungCancerPeople in Winters, CA this weekend at @don450sl’s 10 year LC survival shindig! See you…
Henning Willers, MD @HenningWillers
RT @BrendonStilesMD: What we need is a full on #lcsm retreat to discuss our path forward, how we should shape our social media strategy, an…
Emily M 💐 @7Willow33
RT @garyleethompson: Joining #lcsm in honor of a friend who was just diagnosed with Stage 4 #lungcancer Early 40s. Non-smoker. Still in sho…
KC Dill @kasedill
RT @BrendonStilesMD: What we need is a full on #lcsm retreat to discuss our path forward, how we should shape our social media strategy, an…
#LCSM Chat @lcsmchat
RT @HenningWillers: @BrendonStilesMD Spain is tempting but #radonc ASTRO meeting in Chicago in September is also nice ... you'll here about…
#LCSM Chat @lcsmchat
RT @BenjaminKingMD1: Closing thoughts: so much promise, new class of medications (#immunooncology), but still far to go to treat and cure p…
Brendon Stiles @BrendonStilesMD
Someone (@DrewMoghanaki) was supposed to invite me. And I am supposed to play basketball with @PercyLeeMD #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: What we need is a full on #lcsm retreat to discuss our path forward, how we should shape our social media strategy, an…
Brendon Stiles @BrendonStilesMD
Signing off! Thanks everyone for participating! #lcsm
Aaron Andersen, MD @adandersen
@BrendonStilesMD Thank you for all you do. It makes all the difference to know how many are fighting for us, speaking as a patient advocate. Humbled. #lcsm
Henning Willers, MD @HenningWillers
RT @BenjaminKingMD1: T5. @Dr_RayMak @DanaFarber doing excellent work on functional imaging studies/MRI, genomic predictors for response to…
Henning Willers, MD @HenningWillers
RT @BenjaminKingMD1: T1. Agree. Data shared from meetings needs to be still viewed as such, just because abstracts are tweeted does not mak…
Lung Cancer Sux @LungCancerSux
I’m in!
KC Dill @kasedill
Just a thought does anyone have a list of acronyms used in the #Lcsm tweets to share that would be helpful to patients trying to study and read the tweets and article links? I’m still a newbie and trying to learn all I can.
Matthew Katz, MD @subatomicdoc
RT @JFreemanDaily: @BrendonStilesMD Closing thoughts: Thanks to the amazing @BrendonStilesMD for his solid preparation and sheer number of…
Dr. David Tom Cooke @DavidCookeMD
RT @LungCancerFaces: Hope to see lots of #LungCancerPeople in Winters, CA this weekend at @don450sl’s 10 year LC survival shindig! See you…
Bilal Piperdi @bpiperdi
RT @n8pennell: To put this in context the 2-year OS in ECOG 1594 (published in 2002) was 12%. #lscm https://t.co/l76sLtExnm
Bilal Piperdi @bpiperdi
RT @BrendonStilesMD: T2. Long term results from KEYNOTE-001 with pembrolizumab. 5 year OS of 23.2% in previously untreated patients! #lcs
Stacey Tinianov @coffeemommy
Cancer community peeps w/ connections in New York state: Local friend is looking for integrative oncology support/expertise. Father has metastatic pancreatic cancer & struggling to find a team that will work WITH him on his goals of care. Suggestions? #bcsm #lcsm #gyncsm #hcldr
Oncologia Toracica @oncotoracicamx
RT @drcoronacruz: Queda una semana para enviar abstracts y aplicar para un travel grant a #LALCA19, el próximo viernes 28 de junio es el ci…
goldmask @goldmask123
RT @BrendonStilesMD: T3. Sadly, resistance is a big part of the story for patients on targeted therapy. We have to do more to figure this…
Stephani Page, PhD 👩🏾‍🔬💜 @ThePurplePage
My father battled metastatic pancreatic cancer during my PhD. If you are aware of resources, please share. It makes a world of difference.
Bilal Piperdi @bpiperdi
RT @sjwhitlock: 8.5 years in with stageIV LC I continue to have so much hope for all our futures! Thanks to all. Docs and advocates. We al…
Sally James @jamesian
Sharing with #lcsm chat
Kristy Lamb @KLambPhD
RT @coffeemommy: Cancer community peeps w/ connections in New York state: Local friend is looking for integrative oncology support/expertis…
Lisa Singer, MD, PhD @LisaSingerMDPhD
RT @BenjaminKingMD1: T5. @Dr_RayMak @DanaFarber doing excellent work on functional imaging studies/MRI, genomic predictors for response to…
DAM. MAD. About Breast Cancer @dammadbrstcancr
RT @coffeemommy: Cancer community peeps w/ connections in New York state: Local friend is looking for integrative oncology support/expertis…
Kirang Patel, MD @koolkpMD
RT @RadiologyACR: Strengthen your knowledge of #lungcancer screening best practices. Join us for the Lung Cancer Screening Boot Camp web se…
Henning Willers, MD @HenningWillers
@KellyIrwin_MD @MassDMH @MGHCancerCenter @df_hcc @NorthSuffolkOrg Would love to hear more of your thoughts on supporting patients/advocates to attend conferences #crowdfunding #lcsm
Kim Moran-MacIntosh 🇨🇦 @Kamacintosh
RT @BrendonStilesMD: T3. Sadly, resistance is a big part of the story for patients on targeted therapy. We have to do more to figure this…
Fred Ting @fredtingmd
RT @JCO_ASCO: Neoadjuvant erlotinib for stage IIA-N2 EGFR-mutant non-small cell lung cancer https://t.co/j0uY8gDsmA #lcsm https://t.co/5a4P…
#LCSM Chat @lcsmchat
This may help: https://t.co/JU535Px3qn #lcsm
#LCSM Chat @lcsmchat
RT @adandersen: @BrendonStilesMD Thank you for all you do. It makes all the difference to know how many are fighting for us, speaking as a…
Bingle @TheBingle
Professionals are so amazingly interesting.
Candace Skrapek @cskraps
RT @BrendonStilesMD: #Research moves the needle and saves lives. We have to support it. #lcsm
Jamie Holloway, PhD @jamienholloway
RT @coffeemommy: Cancer community peeps w/ connections in New York state: Local friend is looking for integrative oncology support/expertis…
Rian M. Hasson Charles, M.D. @DrRianCharles
RT @BrendonStilesMD: T5. Nice study from @DrRianCharles on improving screening rates and retention in high risk rural populations. 2.2% i…
Adela @adelapoite
RT @drcoronacruz: Queda una semana para enviar abstracts y aplicar para un travel grant a #LALCA19, el próximo viernes 28 de junio es el ci…
Sam @1SamCosta
RT @JFreemanDaily: Amazingly #lcsm was the top trending hashtag for #ASCO19! #lungcancer has come a long way. https://t.co/H14KVPp6ct
Julia Maues @itsnot_pink
RT @BenjaminKingMD1: T3. How can new technologies e.g "liquid biopsies" allow for us to predict resistance/progession sooner than imaging o…
Deb Smith 🦋🌻🦉🐢🌿 @debsmithbeach
Amazing! #LCSM
Mark Brooke @markbrooke68
Thanks for promoting and sharing @livinglife82 @Lungfoundation is delighted to be hosting this important event on behalf of ALTG
Dr Mukesh Rulaniya @RulaniyaDr
RT @JFreemanDaily: T1: 2/2 To find videos of top lung cancer docs talking about #lungcancer meeting highlights, Google keywords “thoracic c…
Michelle Mills @mrmills1972
RT @coffeemommy: Cancer community peeps w/ connections in New York state: Local friend is looking for integrative oncology support/expertis…
Wafik S. El-Deiry, MD, PhD, FACP @weldeiry
The latest The Cancer Plus Daily! https://t.co/IMS5a1jRON Thanks to @rachanadixit @darrenwalker @DrJudyStone #lcsm #asco19
KC Dill @kasedill
@lcsmchat Many thanks, I have never noticed that! Printing for reference! #Lcsm
Brian Chutskoff @BrianChutskoff
#MBC
Dani Taylor @danimarietaylor
RT @coffeemommy: Cancer community peeps w/ connections in New York state: Local friend is looking for integrative oncology support/expertis…
KC Dill @kasedill
RT @lcsmchat: This may help: https://t.co/JU535Px3qn #lcsm https://t.co/6Y5DNFqPoR
Timothy Craig Allen @TimAllenMDJD
RT @lcsmchat: This may help: https://t.co/JU535Px3qn #lcsm https://t.co/6Y5DNFqPoR
Rosie VMcPh @btraedora
RT @TestLungCancer: PGA golf champion Jason Day’s mom taught him to never give up. Find out why they are encouraging other people facing #l
Bollam Rajesh @BollamRajesh4
RT @StephenVLiu: #CIOT19 #PatrickForde reviewing adjuvant & neoadjuvant immunotherapy in #NSCLC - safe but risk of jeopardizing surgery exi…
Tam Walton @kaydies66
Learn about lung SPOREs: https://t.co/92ZgN6v3ch @utsw @CUCancerCenter @YaleCancer @MDAndersonNews
Benjamin Lok, MD @BenLok
Wow - proud (and lucky) to have our recent paper published @JTOonline ! Congrats to editor-in-chief @DrAlexAdjei and @IASLC team in growing this journal that disseminates important research towards improving outcomes of patients with lung cancer!
OurWarOnCancer @OurWarOnCancer
RT @LungCancerFaces: Hope to see lots of #LungCancerPeople in Winters, CA this weekend at @don450sl’s 10 year LC survival shindig! See you…
OurWarOnCancer @OurWarOnCancer
RT @VirginiaMByrne: Tens of thousands of women are dying & will die from lung cancer & it's mutations this YEAR. I think this stinks, too,…
OurWarOnCancer @OurWarOnCancer
RT @BrendonStilesMD: T3. Sadly, resistance is a big part of the story for patients on targeted therapy. We have to do more to figure this…
OurWarOnCancer @OurWarOnCancer
RT @n8pennell: This is an emergency and must be addressed. Reports from academic centers that routinely test for molecular targets have giv…
OurWarOnCancer @OurWarOnCancer
RT @BrendonStilesMD: What we need is a full on #lcsm retreat to discuss our path forward, how we should shape our social media strategy, an…
OurWarOnCancer @OurWarOnCancer
RT @BrendonStilesMD: #Research moves the needle and saves lives. We have to support it. #lcsm
OurWarOnCancer @OurWarOnCancer
RT @BenjaminKingMD1: T3. How can new technologies e.g "liquid biopsies" allow for us to predict resistance/progession sooner than imaging o…
OurWarOnCancer @OurWarOnCancer
RT @BrendonStilesMD: T5. Nice study from @DrRianCharles on improving screening rates and retention in high risk rural populations. 2.2% i…
OurWarOnCancer @OurWarOnCancer
RT @BrendonStilesMD: T4. Lots of excitement about a drug targeting KRAS – long thought to be “undruggable”. #lcsm https://t.co/XQjmkTnsEc…
OurWarOnCancer @OurWarOnCancer
RT @JFreemanDaily: T4: Oncology meetings are including more on patient experience. One poster at #ASCO19 found broadening clinical trial el…
OurWarOnCancer @OurWarOnCancer
RT @BrendonStilesMD: And as always…#LungCancer has been a hot topic! #lcsm https://t.co/Mo1ifNloqA
OurWarOnCancer @OurWarOnCancer
RT @JFreemanDaily: T1: 2/2 To find videos of top lung cancer docs talking about #lungcancer meeting highlights, Google keywords “thoracic c…
OurWarOnCancer @OurWarOnCancer
RT @BrendonStilesMD: Lots of stuff happening in the RET space! #lcsm https://t.co/PF0L955kzh
OurWarOnCancer @OurWarOnCancer
RT @livinglife82: If you are interested in learning about #clinicaltrials & how you can become more involved in #lungcancer #research, regi…
OurWarOnCancer @OurWarOnCancer
Most people who r diagnosed w/ #lungcancer are NOT current smokers, or have never smoked. If U have lungs, U can get lung cancer. Smokers don't deserve cancer. NO ONE deserves cancer. We must fund the research 2 make stage IV a manageable chronic disease @NCIDrDougLowy #LCSM https://t.co/f1tvmufSDG
Virginia M. Byrne @VirginiaMByrne
That's nice, Liza. Thank you to all the patient advocates who raised hell on Twitter. We all helped @CancerCareMASCC realize the power of cancer surivors. May they never plan to discuss us without inviting us again, which was a sham. 😂 #lcsm #bcsm #hcsm @MayoClinic
Virginia M. Byrne @VirginiaMByrne
My dear friend Dorothy died of a heart attack last January. She didn't know what the signs of a heart attack were. She left a stunned husband & 4 kids. Please know & get help! #lcsm #bcsm #hcsm
Cyrus Khandanpour @c_khandanpour
RT @StephenVLiu: Proposed algorithm by #PatrickForde for incorporating radiation (or not) in #EGFR #NSCLC when TKI is highly CNS penetrant…
Virginia M. Byrne @VirginiaMByrne
Yes! Lung Cancer kills more women than breast cancer & colon cancer combined! Yet lung cancer research is underfunded due to stigma. Let's save lives! Fund lung cancer research NOW!#LCSM #BCSM @NIHDirector @SenatorMenendez @CoryBooker
Virginia M. Byrne @VirginiaMByrne
RT @JFreemanDaily: T4: Oncology meetings are including more on patient experience. One poster at #ASCO19 found broadening clinical trial el…
Global Radiology CME @GlobalRadCME
RT @ellakaz: Take a look at my tweets on LUNGRADS 1.1 updates - designed to reduce false positives over prior historical publications using…
Virginia M. Byrne @VirginiaMByrne
RT @BrendonStilesMD: What we need is a full on #lcsm retreat to discuss our path forward, how we should shape our social media strategy, an…
Virginia M. Byrne @VirginiaMByrne
RT @JFreemanDaily: T1: 2/2 To find videos of top lung cancer docs talking about #lungcancer meeting highlights, Google keywords “thoracic c…
Katsuaki Maehara Ph.D @KatsuakiMaehara
RT @JTOonline: Today, we learned that our #impactfactor for 2018 is 12.460 - up from 10.336 in 2017! The JTO now ranks 10th of all #oncolog
Katsuaki Maehara Ph.D @KatsuakiMaehara
RT @IASLC: Abstract submission for our 2019 North America Conference on #LungCancer will close June 28th! Don't forget to submit your abst…
Virginia M. Byrne @VirginiaMByrne
This is wonderful! We also need this for women with lung cancer and lung cancer mutations. #LCSM #BCSM #hcsm #TreatCancersEqually
Katsuaki Maehara Ph.D @KatsuakiMaehara
RT @OncoAlert: A heartfelt congratulations @JTOonline !! Kudos on a amazing job!!! Best from @your friends at @OncoAlert ! https://t.co/lZ…
Katsuaki Maehara Ph.D @KatsuakiMaehara
RT @BrendonStilesMD: What we need is a full on #lcsm retreat to discuss our path forward, how we should shape our social media strategy, an…
Chiara CATANIA @ChiaraCATANIA4
RT @JTOonline: In the latest JTO Editor’s Choice, we present a study conducted by Negrao and his colleagues regarding predictive biomarkers…
Dr. Antonio Calles @Tony_Calles
RT @JFreemanDaily: Amazingly #lcsm was the top trending hashtag for #ASCO19! #lungcancer has come a long way. https://t.co/H14KVPp6ct
Katsuaki Maehara Ph.D @KatsuakiMaehara
RT @IASLC: IASLC #SCLC19 TV - These included one by Dr. Lovly on using blood to look for tumor DNA, which can monitor the response of #SCLC
Katsuaki Maehara Ph.D @KatsuakiMaehara
RT @IASLC: IASLC #SCLC19 Tweet II - Organized Julie George, @TGOliver2, J.T. Poirier and @teekayowo, #SCLC19 was a multidisciplinary event…
Katsuaki Maehara Ph.D @KatsuakiMaehara
RT @notahedge: @VivekSubbiah talking about the evolution of RET inhibitors at the BCM-MDACC Joint Drug Development Symposium @MDAndersonNew
Alfredo Addeo MD @Alfdoc2
Does WBRT have still a role?
Katsuaki Maehara Ph.D @KatsuakiMaehara
RT @JFreemanDaily: T1: 2/2 To find videos of top lung cancer docs talking about #lungcancer meeting highlights, Google keywords “thoracic c…
Katsuaki Maehara Ph.D @KatsuakiMaehara
RT @BrendonStilesMD: T3. Sadly, resistance is a big part of the story for patients on targeted therapy. We have to do more to figure this…
Katsuaki Maehara Ph.D @KatsuakiMaehara
RT @BenjaminKingMD1: T3. How can new technologies e.g "liquid biopsies" allow for us to predict resistance/progession sooner than imaging o…
Sophie @misssophiebot
RT @VirginiaMByrne: This is wonderful! We also need this for women with lung cancer and lung cancer mutations. #LCSM #BCSM #hcsm #TreatCanc
Katsuaki Maehara Ph.D @KatsuakiMaehara
RT @JFreemanDaily: Amazingly #lcsm was the top trending hashtag for #ASCO19! #lungcancer has come a long way. https://t.co/H14KVPp6ct
VonVictor V. Rosenchild | HubBucket Founder & CEO @Rosenchild
RT @RadiologyACR: Strengthen your knowledge of #lungcancer screening best practices. Join us for the Lung Cancer Screening Boot Camp web se…
Selene Seltzer @SeleneSeltzer
RT @coffeemommy: Cancer community peeps w/ connections in New York state: Local friend is looking for integrative oncology support/expertis…
Renee Alexander @ReneeAmbrosio
RT @FDAOncology: FDA granted accelerated approval to pembrolizumab (KEYTRUDA, Merck) for patients with metastatic small cell lung cancer (S…
Jose F. Corona-Cruz @drcoronacruz
RT @JTOonline: In the latest JTO Editor’s Choice, we present a study conducted by Negrao and his colleagues regarding predictive biomarkers…
Virginia M. Byrne @VirginiaMByrne
I hope there's more focus & new medications for all people living with #metastatic cancer. #lcsm #bcsm @NIHDirector @NCIDrDougLowy
VirCabal @CabalVir
RT @theNCI: What's happening in lung cancer research? Here's an update on some of the latest findings on how to prevent, detect, and treat…
OncoAlert @OncoAlert
RT @UmbertoMalapel1: @OncoAlert https://t.co/OtwZtTKx4R
Umberto Malapelle @UmbertoMalapel1
RT @BrendonStilesMD: T3. Sadly, resistance is a big part of the story for patients on targeted therapy. We have to do more to figure this…
Marilyn Nelson @MarilynNelson55
@DrewMoghanaki @findlungcancer @LeciaSequist @VPrasadMDMPH @BrendonStilesMD @CrisAlvaradoMD @SethBKrantz @kennylinafp @lown @AFPJournal @ShannonBrownlee @JeanneLenzer1 @chrisdraft @Pattybeatslungc @biniamkidaneMD @chrisslatore @PercyLeeMD @jillfeldman4 @JillHW @Kamacintosh @ivybelkins @aesfCEO @ellakaz @oncology_bg Like anti-vaxers and climate change deniers, anti-screening ppl continue to deny despite compelling evidence of benefits, lives saved, and cost-effectiveness. #lcsm
denis Moro-Sibilot @DMSLung
RT @UmbertoMalapel1: @OncoAlert https://t.co/OtwZtTKx4R
Pasquale Pisapia @PasqualePisapia
RT @mtmdphd: Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mut…
Pasquale Pisapia @PasqualePisapia
RT @IASLC: IASLC #SCLC19 Tweet VI - Finally, there was a presentation by Dr. Julien Sage on understanding how #SCLC metastasizes by studyin…
AMJ @AMJJournals
RT @theNCI: What's happening in lung cancer research? Here's an update on some of the latest findings on how to prevent, detect, and treat…
Julien Mazieres @JulienMazieres
RT @DMSLung: A great honor and a great moment at #IFCT Frances Shepherd gives a lecture on the history of progress in lung cancer #LCSM #Pa
21st Century Ed @theLegacyPrep
RT @OurWarOnCancer: Most people who r diagnosed w/ #lungcancer are NOT current smokers, or have never smoked. If U have lungs, U can get lu…
M JOSE SERRANO @MJOSESERRANO19
RT @OncoAlert: A heartfelt congratulations @JTOonline !! Kudos on a amazing job!!! Best from @your friends at @OncoAlert ! https://t.co/lZ…
Marie Wislez @MarieWislez
RT @JFreemanDaily: Amazingly #lcsm was the top trending hashtag for #ASCO19! #lungcancer has come a long way. https://t.co/H14KVPp6ct
Marilyn Nelson @MarilynNelson55
RT @livinglife82: If you are interested in learning about #clinicaltrials & how you can become more involved in #lungcancer #research, regi…
GOECP @goecp1
RT @BrendonStilesMD: Welcome to our #LCSM chat. Hoping that lots of people will join tonight! #lcsm
GOECP @goecp1
RT @BrendonStilesMD: I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to fol…
GOECP @goecp1
RT @JTOonline: In the latest JTO Editor’s Choice, we present a study conducted by Negrao and his colleagues regarding predictive biomarkers…
Oncology Forum UK @OncologyForum
RT @JFreemanDaily: Amazingly #lcsm was the top trending hashtag for #ASCO19! #lungcancer has come a long way. https://t.co/H14KVPp6ct
Oncology Advance @OncologyAdvance
RT @JTOonline: In the latest JTO Editor’s Choice, we present a study conducted by Negrao and his colleagues regarding predictive biomarkers…
Oncology Advance @OncologyAdvance
RT @JTOonline: Today, we learned that our #impactfactor for 2018 is 12.460 - up from 10.336 in 2017! The JTO now ranks 10th of all #oncolog
Joaquín J Cabrera @JoaquinJCabrera
RT @JTOonline: In the latest JTO Editor’s Choice, we present a study conducted by Negrao and his colleagues regarding predictive biomarkers…
Joaquín J Cabrera @JoaquinJCabrera
RT @_ShankarSiva: It's here! SABR-COMET published in @TheLancet - https://t.co/lZmAYZ3xWK - randomised trial of ablation in oligometastast…
Oncocluster @Oncocluster
The latest The Oncology Daily! https://t.co/c0IC2d3U07 Thanks to @jaziehoncology @McFoggia @ErikaHamilton9 #cancer #lcsm
Cancer Library VCC @VCCLibrary
RT @JOP_ASCO: Effectiveness of implementing a community-based lung cancer screening program #lcsm https://t.co/24i6kshS5w https://t.co/OB8…
Autodidact @iamukasa
RT @VirginiaMByrne: This is wonderful! We also need this for women with lung cancer and lung cancer mutations. #LCSM #BCSM #hcsm #TreatCanc
Rex Michael Santiago @Rex_Ogaitnas
RT @JTOonline: In the latest JTO Editor’s Choice, we present a study conducted by Negrao and his colleagues regarding predictive biomarkers…
Arutha Kulasinghe @aruthak
RT @JTOonline: Today, we learned that our #impactfactor for 2018 is 12.460 - up from 10.336 in 2017! The JTO now ranks 10th of all #oncolog
Legasil @Legasil1
RT @StephenVLiu: #OncoAlert Pembrolizumab receives FDA accelerated approval for 3rd line and beyond #SCLC - approval based on KEYNOTE-028 a…
Stephen V Liu @StephenVLiu
#CIOT19 Opening lecture day 2 by @marinagarassino reviewing the tremendous progress in #ALK and #ROS1 #NSCLC. The first and last lecture at CIOT are in Italian. But we’re fluent in KM curves! Important stress on ALK TKI resistance and great work by @JustinGainor. #LCSM #OncoAlert https://t.co/2JGNKgejai
Elad Sharon @EladSharonMD
RT @StephenVLiu: #CIOT19 lively head to head debate on management of brain metastases in oncogene-driven #NSCLC by #PatrickForde and #Matte
Elad Sharon @EladSharonMD
RT @StephenVLiu: Proposed algorithm by #PatrickForde for incorporating radiation (or not) in #EGFR #NSCLC when TKI is highly CNS penetrant…
Martín Lázaro @mlazqui
El olfato canino tiene una precisión del 97% en la detección del #cáncer de #pulmón (J Am Osteop Assoc) #lcsm #lungcancer https://t.co/V8Yj1mv9Gl
Stephen V Liu @StephenVLiu
#CIOT19 IO session chaired by @marinagarassino starts with @ValiPap reviewing nivo/ipi - impressive and real differences in PFS and duration of response but waiting for OS data. Perhaps even more promise in early stage setting. #LCSM #OncoAlert https://t.co/NDHTvzqguO
Stephen V Liu @StephenVLiu
#CIOT19 review of durva/treme by #ManuelCobo - did not see OS benefit using 25% cutoff. Intriguing benefit in patients with high blood #TMB worth a closer look. #LCSM #OncoAlert https://t.co/c5Q2BQBpc1
OncoAlert @OncoAlert
RT @StephenVLiu: #CIOT19 review of durva/treme by #ManuelCobo - did not see OS benefit using 25% cutoff. Intriguing benefit in patients wit…
OncoAlert @OncoAlert
RT @StephenVLiu: #CIOT19 IO session chaired by @marinagarassino starts with @ValiPap reviewing nivo/ipi - impressive and real differences i…
OncoAlert @OncoAlert
RT @StephenVLiu: #CIOT19 Opening lecture day 2 by @marinagarassino reviewing the tremendous progress in #ALK and #ROS1 #NSCLC. The first an…
Stephen V Liu @StephenVLiu
#CIOT19 Provocative discussion about the role of TMB and how to view post hoc subset analyses. Nice interchange led by @marinagarassino @ValiPap #ManuelCobo and questions by #LuisPazAres - consensus is that OS remains the key. TMB fairly crude and will evolve #LCSM #OncoAlert https://t.co/cBxYm0kcok
Alfredo Addeo MD @Alfdoc2
Re TMB in checkmate227 I have always thought that, given the modification occurred at the study, the trial was not “equipped” to reach significant OS anyway. Re Ioi-nivo earlier, I was not too impressed by the Neostar data presented at @asco2019 but worth exploring further
Michael McCarty @memccarty1
RT @OurWarOnCancer: Most people who r diagnosed w/ #lungcancer are NOT current smokers, or have never smoked. If U have lungs, U can get lu…
OncoAlert @OncoAlert
RT @StephenVLiu: #CIOT19 Provocative discussion about the role of TMB and how to view post hoc subset analyses. Nice interchange led by @ma
Lung Cancer Europe @LungCancerEu
RT @JTOonline: JTO Research Watch: "Prophylactic Irradiation of Tracts in Patients with Malignant Pleural Mesothelioma: An Open-Label, Mult…
Elizabeth L. Dickson, MD, FACOG @edicksonMD
RT @BrendonStilesMD: T3. Sadly, resistance is a big part of the story for patients on targeted therapy. We have to do more to figure this…
denis Moro-Sibilot @DMSLung
@GerardZalcman Lecture on mesothelioma. #IFCT annual meeting #LCSM #Paris https://t.co/6pbTEs4WbI
Targeted Oncology @TargetedOnc
“We’re really in the initial stages of beginning to understand the mechanisms of resistance to third-generation tyrosine kinase inhibitors when these are used in the first-line setting and in the second-line setting,” said Dr. Politi. https://t.co/F2S1Weezyi #NSCLC #lcsm
TranslationalGenomic @TGEGatONJCRI
RT @JTOonline: Today, we learned that our #impactfactor for 2018 is 12.460 - up from 10.336 in 2017! The JTO now ranks 10th of all #oncolog
Drew Moghanaki @DrewMoghanaki
A few, and really only a few, have suggested @VPrasadMDMPH might be an ANTI-SCREENER. But, I’ve had to stop them and ask if they are the ones who are in an echo chamber. As he said, he’s open to seeing data that shows its impact. So, let’s show him! #lcsm
Princess Margaret Cancer Centre Research @PMResearch_UHN
RT @BenLok: Wow - proud (and lucky) to have our recent paper published @JTOonline ! Congrats to editor-in-chief @DrAlexAdjei and @IASLC tea…
Vamsi Velcheti, MD @VamsiVelcheti
RT @DrewMoghanaki: A few, and really only a few, have suggested @VPrasadMDMPH might be an ANTI-SCREENER. But, I’ve had to stop them and ask…
Vamsi Velcheti, MD @VamsiVelcheti
RT @MarilynNelson55: @DrewMoghanaki @findlungcancer @LeciaSequist @VPrasadMDMPH @BrendonStilesMD @CrisAlvaradoMD @SethBKrantz @kennylinafp
Vamsi Velcheti, MD @VamsiVelcheti
@n8pennell perhaps starting a new hashtag for patient focused information?? just a thought perhaps #LCSMpatient #LCSM
Stephen V Liu @StephenVLiu
#CIOT19 has a great format: lectures, debates, scientific sessions and “Arena” - topic was chemo/IO: #LuisPazAres pembro, @EnriquetaFelip atezo and @javierDcastro nivo. Really enjoying the innovative topics and perspectives here. #LCSM https://t.co/1YWjIdDRDA
DOLORES ISLA @isla_dolores
Fantastic and relevant spanish participation !! Very proud !!
Alfredo Addeo MD @Alfdoc2
Interesting format.
Tobey @BRCAinfo
RT @coffeemommy: Cancer community peeps w/ connections in New York state: Local friend is looking for integrative oncology support/expertis…
Mike Thompson, MD, PhD, FASCO @mtmdphd
RT @n8pennell: Despite this we had not one #LCSM person among the top influencers! I think this is because we had such broad spread of peop…
Mike Thompson, MD, PhD, FASCO @mtmdphd
RT @JFreemanDaily: Amazingly #lcsm was the top trending hashtag for #ASCO19! #lungcancer has come a long way. https://t.co/H14KVPp6ct
OncoAlert @OncoAlert
RT @StephenVLiu: #CIOT19 has a great format: lectures, debates, scientific sessions and “Arena” - topic was chemo/IO: #LuisPazAres pembro,…
Mike Thompson, MD, PhD, FASCO @mtmdphd
RT @n8pennell: To put this in context the 2-year OS in ECOG 1594 (published in 2002) was 12%. #lscm https://t.co/l76sLtExnm
Rynn @Krug7499
RT @OurWarOnCancer: Most people who r diagnosed w/ #lungcancer are NOT current smokers, or have never smoked. If U have lungs, U can get lu…
SATYAM SINGH @satyamsingh2704
RT @StephenVLiu: #CIOT19 review of durva/treme by #ManuelCobo - did not see OS benefit using 25% cutoff. Intriguing benefit in patients wit…
Marco Tagliamento @tagliamento_m
RT @StephenVLiu: #CIOT19 has a great format: lectures, debates, scientific sessions and “Arena” - topic was chemo/IO: #LuisPazAres pembro,…
Brendon Stiles @BrendonStilesMD
@DrewMoghanaki @VamsiVelcheti @kennylinafp @CrisAlvaradoMD @lown @AFPJournal @ShannonBrownlee @JeanneLenzer1 @VPrasadMDMPH @chrisdraft @Pattybeatslungc @biniamkidaneMD @chrisslatore @PercyLeeMD @jillfeldman4 @JillHW @Kamacintosh @ivybelkins @aesfCEO Oh, the irony... Anyone know who these two are? They are featured every year in my medical student lung cancer lecture. #lcsm #tssmn https://t.co/F99PWhsEI1
Kim Moran-MacIntosh 🇨🇦 @Kamacintosh
My first political endeavour @ the 🇨🇦 Federal Gov't Level #LCDT #LCSM #LungCancer #researchmatters
Elad Sharon @EladSharonMD
RT @StephenVLiu: #CIOT19 Provocative discussion about the role of TMB and how to view post hoc subset analyses. Nice interchange led by @ma
Antonio Passaro, MD PhD @APassaroMD
RT @StephenVLiu: #CIOT19 has a great format: lectures, debates, scientific sessions and “Arena” - topic was chemo/IO: #LuisPazAres pembro,…
Andrea Borondy Kitts @findlungcancer
RT @MarilynNelson55: @DrewMoghanaki @findlungcancer @LeciaSequist @VPrasadMDMPH @BrendonStilesMD @CrisAlvaradoMD @SethBKrantz @kennylinafp
Dave Bjork @bjork5
RT @BrendonStilesMD: What we need is a full on #lcsm retreat to discuss our path forward, how we should shape our social media strategy, an…
Kim Moran-MacIntosh 🇨🇦 @Kamacintosh
#LCSM #LungCancer #LDCT #researchmatters
Kim Moran-MacIntosh 🇨🇦 @Kamacintosh
RT @BrendonStilesMD: Time to stop the blame game in lung cancer and embrace education and screening for lung cancer. If you have lungs, yo…
Dave Bjork @bjork5
@BrendonStilesMD Nice! This is interesting. My friends at @BlueprintMeds are working on this...I am hopeful! #lcsm @martamurcia1 👏🏻
Tom Varghese Jr. MD @TomVargheseJr
RT @BrendonStilesMD: #Research moves the needle and saves lives. We have to support it. #lcsm
Tom Varghese Jr. MD @TomVargheseJr
RT @BrendonStilesMD: T1. One important thing to remember: a lot of presentations haven’t been peer reviewed or disclosed all data. Easy t…
Tom Varghese Jr. MD @TomVargheseJr
RT @JFreemanDaily: Amazingly #lcsm was the top trending hashtag for #ASCO19! #lungcancer has come a long way. https://t.co/H14KVPp6ct
Enlightening Results @GraceCordovano
RT @n8pennell: This is an emergency and must be addressed. Reports from academic centers that routinely test for molecular targets have giv…
Enlightening Results @GraceCordovano
RT @BrendonStilesMD: Lots of stuff happening in the RET space! #lcsm https://t.co/PF0L955kzh
Enlightening Results @GraceCordovano
RT @BrendonStilesMD: #Research moves the needle and saves lives. We have to support it. #lcsm
Enlightening Results @GraceCordovano
RT @HenningWillers: @BrendonStilesMD T2. PACIFIC really broke through the ceiling for stage III #lung cancer #lcsm
Enlightening Results @GraceCordovano
@n8pennell @subatomicdoc Definitely doesn’t need to be either or; patient & carepartner inclusion enhances & enriches the conversations, questions, & takeaways. Need all voices to have a conversation. #LCSM #AskPatients
Bartomeu Massuti @bmassutis
RT @StephenVLiu: Proposed algorithm by #PatrickForde for incorporating radiation (or not) in #EGFR #NSCLC when TKI is highly CNS penetrant…
Targeted Oncology @TargetedOnc
Dr. Burns says he conducts next-generation sequencing testing on all patients with metastatic and nonsquamous lung cancers. This includes patients that are both smokers and non-smokers. https://t.co/B05Qn33hFD #LungCancers #LCsm
Javier de Castro @javierDcastro
RT @StephenVLiu: #CIOT19 has a great format: lectures, debates, scientific sessions and “Arena” - topic was chemo/IO: #LuisPazAres pembro,…
T.J. Martell Foundation @tjmartell
RT @nciprevention: Are you confused about what kind of tests you should get when to stay healthy? Here is a Cheat Sheet for Women's Cancer Screenings and Good Health from @CDC_Cancer https://t.co/L2FC61cGQE #bcsm #gyncsm #lcsm https://t.co/gNuyPnmszi https://t.co/iVMJoTjwSz
OneDayAtATime @AtkinsonNancy
RT @tjmartell: RT @nciprevention: Are you confused about what kind of tests you should get when to stay healthy? Here is a Cheat Sheet for…
dough @semodough
$BPMC $LLY
dough @semodough
RT @n8pennell: This is an emergency and must be addressed. Reports from academic centers that routinely test for molecular targets have giv…
Marina Garassino @marinagarassino
RT @StephenVLiu: #CIOT19 Provocative discussion about the role of TMB and how to view post hoc subset analyses. Nice interchange led by @ma
Eric Bernicker @EricBernicker
More data suggesting that multiplex NGS testing wwould lead to better chances of discovering actionable mutations...#LCSM MET IHC is a Poor Screen for MET Amplification or MET exon 14 mutations in Lung Adenocarcinomas https://t.co/y3T5Ct8J9s
Stephen V Liu @StephenVLiu
#CIOT19 #ShirishGadgeel presenting #EGFR updates. Osimertinib still SOC but highlighting TKI+chemo combinations and excellent work by @VanitaNoronha at #ASCO19 - looking forward to exploration of osi + chemo #LCSM #OncoAlert https://t.co/5MmyOCvqJD
MOC Brasil @MOCBrasil
RT @MOCBrasil: Imunoterapia aprovada para o tratamento do câncer de pulmão de células pequenas no Brasil A aprovação destina-se à 1L do Ca…
Fernando J. de Miguel @fdemiguelsdp
RT @JTOonline: Today, we learned that our #impactfactor for 2018 is 12.460 - up from 10.336 in 2017! The JTO now ranks 10th of all #oncolog
Claudia @clamate6986
RT @BrendonStilesMD: T3. Sadly, resistance is a big part of the story for patients on targeted therapy. We have to do more to figure this…
Rynn @Krug7499
RT @BrendonStilesMD: Time to stop the blame game in lung cancer and embrace education and screening for lung cancer. If you have lungs, yo…
Antonio Passaro, MD PhD @APassaroMD
#CIOT19 @StephenVLiu discussing the optimal sequencing in ALK-positive #LungCancer #lcsm Improving survival optimising the available drugs https://t.co/KY2IaMCiaH
Denise Marshall @DeniseM79772878
RT @BrendonStilesMD: #Research moves the needle and saves lives. We have to support it. #lcsm
Vanita Noronha @VanitaNoronha
RT @StephenVLiu: #CIOT19 #ShirishGadgeel presenting #EGFR updates. Osimertinib still SOC but highlighting TKI+chemo combinations and excell…
OncoAlert @OncoAlert
RT @APassaroMD: #CIOT19 @StephenVLiu discussing the optimal sequencing in ALK-positive #LungCancer #lcsm Improving survival optimising the…
OncoAlert @OncoAlert
RT @StephenVLiu: #CIOT19 #ShirishGadgeel presenting #EGFR updates. Osimertinib still SOC but highlighting TKI+chemo combinations and excell…
Janet Freeman-Daily @JFreemanDaily
Do you remember when you joined Twitter? I do! #MyTwitterAnniversary #LCSM https://t.co/4niqG4WO31
Dr. Matthew Schabath @MatthewSchabath
The latest issue of 'Science, Society, and Sports'! https://t.co/1TiWdWVt16 Thanks to @FiolYadyra @PCA_TampaBay @LeinesBryan #lcsm #science
magallen lee @MonckyD
RT @StephenVLiu: #CIOT19 IO session chaired by @marinagarassino starts with @ValiPap reviewing nivo/ipi - impressive and real differences i…
Oncology State Societies at ACCC @OSSatACCC
ACCC is proud to work with @accpchest, @LUNGevity & @IASLC on a new initiative designed to improve care coordination and outcomes for patients with non-small cell lung #cancer. In collaboration with @AstraZenecaUS. Read more here: https://t.co/9OjlXnQaKG #lungcancer #NSCLC #lcsm
Pasquale Pisapia @PasqualePisapia
RT @StephenVLiu: #CIOT19 #ShirishGadgeel presenting #EGFR updates. Osimertinib still SOC but highlighting TKI+chemo combinations and excell…
Pasquale Pisapia @PasqualePisapia
RT @APassaroMD: #CIOT19 @StephenVLiu discussing the optimal sequencing in ALK-positive #LungCancer #lcsm Improving survival optimising the…
Pasquale Pisapia @PasqualePisapia
RT @StephenVLiu: #CIOT19 Opening lecture day 2 by @marinagarassino reviewing the tremendous progress in #ALK and #ROS1 #NSCLC. The first an…
OncoAlert @OncoAlert
RT @n8pennell: Despite this we had not one #LCSM person among the top influencers! I think this is because we had such broad spread of peop…
Kim Moran-MacIntosh 🇨🇦 @Kamacintosh
RT @AboutLungCancer: #lcsm #Lungcancerscreening saves lives, and women are almost twice as likely to die from lung cancer than breast cance…
Test Lung Cancer @TestLungCancer
PGA golf champion Jason Day’s mom taught him to never give up. Find out why they are encouraging other people facing #lungcancer to do the same. #LCSM
Test Lung Cancer @TestLungCancer
PGA golf champion Jason Day’s mom taught him to never give up. Find out why they are encouraging other people facing #lungcancer to do the same. #LCSM
Stephen V Liu @StephenVLiu
RT @APassaroMD: #CIOT19 @StephenVLiu discussing the optimal sequencing in ALK-positive #LungCancer #lcsm Improving survival optimising the…
Targeted Oncology @TargetedOnc
RT @Kamacintosh: Genomic Testing and Targeted Therapies May be Underused in Community Practice only 7% are test for all 7 #biomarkers, Stud…
Henning Willers, MD @HenningWillers
RT @JFreemanDaily: I am encouraged by progress in so many areas of #lungcancer research--different stages, different biomarkers, different…
Mohana Roy @MohanaRoy1
RT @StephenVLiu: #CIOT19 #ShirishGadgeel presenting #EGFR updates. Osimertinib still SOC but highlighting TKI+chemo combinations and excell…
Henning Willers, MD @HenningWillers
RT @JFreemanDaily: T1: 1/2 Increasingly, #lungcancer news from medical meetings is being shared on social media. Good way to find important…
Henning Willers, MD @HenningWillers
RT @JFreemanDaily: Amazingly #lcsm was the top trending hashtag for #ASCO19! #lungcancer has come a long way. https://t.co/H14KVPp6ct
dr_felicity_harper @drfelicityharp1
RT @theNCI: What's happening in lung cancer research? Here's an update on some of the latest findings on how to prevent, detect, and treat…
Israel Rodriguez A @israelo430
RT @JTOonline: In the latest JTO Editor’s Choice, we present a study conducted by Negrao and his colleagues regarding predictive biomarkers…
Stephen V Liu @StephenVLiu
#CIOT19 Debate: pembro alone (@EnriquetaFelip)or chemo/IO (@ValiPap) for PDL1 high #NSCLC - does the toxicity justify potential benefit? Debates will continue until we see #INSIGNA results (@HosseinBorghaei - can you expedite? Thanks) #LCSM #OncoAlert https://t.co/5pflfdUsh6
Geraldine McGinty @DrGMcGinty
RT @BrendonStilesMD: #Research moves the needle and saves lives. We have to support it. #lcsm
Chris Kriz MHA CHCP @cQIme
RT @PeerView: New CME/MOC/CNE activity with Drs. @annaffarago @StephenVLiu & @HornLeora: How should novel therapies be integrated into trea…
Carolyn Thomas @HeartSisters
RT @VirginiaMByrne: My dear friend Dorothy died of a heart attack last January. She didn't know what the signs of a heart attack were. She…
Dr. David Tom Cooke @DavidCookeMD
RT @lcsmchat: This may help: https://t.co/JU535Px3qn #lcsm https://t.co/6Y5DNFqPoR
ATS TO Assembly @atstoa
RT @JTOonline: In the latest JTO Editor’s Choice, we present a study conducted by Negrao and his colleagues regarding predictive biomarkers…
Marco Tagliamento @tagliamento_m
RT @StephenVLiu: #CIOT19 Debate: pembro alone (@EnriquetaFelip)or chemo/IO (@ValiPap) for PDL1 high #NSCLC - does the toxicity justify pote…
Mohana Roy @MohanaRoy1
RT @StephenVLiu: #CIOT19 Debate: pembro alone (@EnriquetaFelip)or chemo/IO (@ValiPap) for PDL1 high #NSCLC - does the toxicity justify pote…
Rodolfo Chicas-Sett⚡️⚡️ @OncoRod
RT @OncoAlert: A heartfelt congratulations @JTOonline !! Kudos on a amazing job!!! Best from @your friends at @OncoAlert ! https://t.co/lZ…
Dr. David Tom Cooke @DavidCookeMD
RT @BrendonStilesMD: What we need is a full on #lcsm retreat to discuss our path forward, how we should shape our social media strategy, an…
Garrett Green @ggreen1986
RT @StephenVLiu: Proposed algorithm by #PatrickForde for incorporating radiation (or not) in #EGFR #NSCLC when TKI is highly CNS penetrant…
deborahcollyar @deborahcollyar
RT @OurWarOnCancer: Most people who r diagnosed w/ #lungcancer are NOT current smokers, or have never smoked. If U have lungs, U can get lu…
IASLC @IASLC
Today is the last day to participate in our ILCN Readership Survey! Complete this 10-15 minute survey by the end of the day to be entered to win one of THREE free registrations to the 2019 World Conference on Lung Cancer (#WCLC19). #LCSM Survey: https://t.co/aBB556jsNE https://t.co/bjkX58CPEw
Rynn @Krug7499
RT @AboutLungCancer: #lcsm #Lungcancerscreening saves lives, and women are almost twice as likely to die from lung cancer than breast cance…
Andres F. Cardona @AndresFCardonaZ
RT @StephenVLiu: #CIOT19 Provocative discussion about the role of TMB and how to view post hoc subset analyses. Nice interchange led by @ma
Sharon C @charbone1
RT @VirginiaMByrne: My dear friend Dorothy died of a heart attack last January. She didn't know what the signs of a heart attack were. She…
Laura Book @LauraJBook
RT @AboutLungCancer: #lcsm #Lungcancerscreening saves lives, and women are almost twice as likely to die from lung cancer than breast cance…
Laura Book @LauraJBook
RT @VirginiaMByrne: Yes! Lung Cancer kills more women than breast cancer & colon cancer combined! Yet lung cancer research is underfunded d…
Alfredo Addeo MD @Alfdoc2
The abstract from @VanitaNoronha was the only possible practice ( if Osi not available)changing presented at #ASCO2019 . I said it before @OncLive and I say it again now #OncoAlert
Dr. Matthew Schabath @MatthewSchabath
RT @BrendonStilesMD: T5. Nice study from @DrRianCharles on improving screening rates and retention in high risk rural populations. 2.2% i…
Eon @eonhealth
@UCLRespiratory @atrembla @uclmedsci Will this seminar be live streamed?#lcsm
GO2 Foundation for Lung Cancer @GO2Foundation
#FactFriday | Happy first day of summer! #LCSM https://t.co/w0cLHuq2Je
Dr. Matthew Schabath @MatthewSchabath
Well said and accurate. As Dr. Aberle and I recently wrote in a commentary on the MILD trial in Nature Reviews: “...we have moved beyond speculation to the evidence of substantial beneficial mortality reductions with LDCT screening...”. Lung cancer screening saves lives. #lcsm
AJ Pollock’s Infected Elbow @MomsOopsBaby
RT @TestLungCancer: PGA golf champion Jason Day’s mom taught him to never give up. Find out why they are encouraging other people facing #l
OncLive SOSS @OncLiveSOSS
Nirav S. Dhruva, MD, discusses the research that is needed to improve outcomes for patients with NSCLC #lcsm https://t.co/pJcKgV3OKj
IASLC @IASLC
IASLC member @HosseinBorghaei discusses the clinical implications of two late-breaking abstracts in #lungcancer that were presented at the #ASCO19 Annual Meeting. #LCSM Read the full article and watch the video: https://t.co/bMgYbG90mB https://t.co/R6iyeK5M2F
deborahcollyar @deborahcollyar
RT @jillfeldman4: @symplur @ASCO @stage4kelly @corrie_painter @double_whammied @womenofteal @jamienholloway @coffeemommy @MyelomaTeacher @l
Faces of Lung Cancer @LungCancerFaces
@Krug7499 @AboutLungCancer @Kamacintosh Many believe that lung cancer is “deserved” due to something the sufferer did. Smoker, former smoker, never-smoker: no one deserves LC or any disease. All deserve fair & equitable research funding & access to correct treatment/diagnostics (like biomarker testing). #lcsm #nostigma
Faces of Lung Cancer @LungCancerFaces
RT @AboutLungCancer: #lcsm #Lungcancerscreening saves lives, and women are almost twice as likely to die from lung cancer than breast cance…
OncoAlert @OncoAlert
RT @Alfdoc2: The abstract from @VanitaNoronha was the only possible practice ( if Osi not available)changing presented at #ASCO2019 . I sai…
OncoAlert @OncoAlert
RT @StephenVLiu: #CIOT19 Debate: pembro alone (@EnriquetaFelip)or chemo/IO (@ValiPap) for PDL1 high #NSCLC - does the toxicity justify pote…
Dr. Deanna Attai @DrAttai
RT @stage4kelly: And the same thing has been found with breast cancer. Bottom line: metastatic cancer isn’t your fault. It’s not because yo…
Faces of Lung Cancer @LungCancerFaces
“Cancer may kill my body but it will never get my spirit. I have decided, yes, decided, that I’m just not going to let my progression get me down.” #lcsm
Umberto Malapelle @UmbertoMalapel1
RT @IASLC: IASLC member @HosseinBorghaei discusses the clinical implications of two late-breaking abstracts in #lungcancer that were presen…
Yu Yang Soon @yysoon01
RT @StephenVLiu: #CIOT19 lively head to head debate on management of brain metastases in oncogene-driven #NSCLC by #PatrickForde and #Matte
OncologyEducation @OncEd
In this new #Oncology Opinions Series, Dr. Corey Langer presents on the therapeutic landscape in advanced #NSCLC: https://t.co/ciaMc1bAE0 #ImmunoOnc #LCSM https://t.co/A48pwXOGqd
Stephen Neagus @B4nowneagusS
I wouldn't give up either if I could come in 197th in a tournament & walk away with $25k. The recent Us Open 1st place $2.5M should enrage every American who lost their share of $19.2T in 2008 created depression for GREED!
Timothy Craig Allen @TimAllenMDJD
RT @LungCancerFaces: “Cancer may kill my body but it will never get my spirit. I have decided, yes, decided, that I’m just not going to let…
Kristin Ito @KAdvocate_LCAM
RT @IASLC: IASLC member @HosseinBorghaei discusses the clinical implications of two late-breaking abstracts in #lungcancer that were presen…
CTSurgSocMedNetwork @tssmn
RT @BrendonStilesMD: @DrewMoghanaki @VamsiVelcheti @kennylinafp @CrisAlvaradoMD @lown @AFPJournal @ShannonBrownlee @JeanneLenzer1 @VPrasadM
magallen lee @MonckyD
RT @JCO_ASCO: Neoadjuvant erlotinib for stage IIA-N2 EGFR-mutant non-small cell lung cancer https://t.co/j0uY8gDsmA #lcsm https://t.co/5a4P…
LungCancerInitiative @LCInitiativeNC
Chad Pecot, MD,@UNC_Lineberger, Lung Cancer Initiative Board Member discusses the frontline standard of care in advanced squamous non–small cell lung cancer. #LCSM #nclungcancer https://t.co/7SkVZIxq76
Brendon Stiles @BrendonStilesMD
@VPrasadMDMPH @MarilynNelson55 @DrewMoghanaki @findlungcancer @LeciaSequist @CrisAlvaradoMD @SethBKrantz @kennylinafp @lown @AFPJournal @ShannonBrownlee @JeanneLenzer1 @chrisdraft @Pattybeatslungc @biniamkidaneMD @chrisslatore @PercyLeeMD @jillfeldman4 @JillHW @Kamacintosh @ivybelkins @aesfCEO @ellakaz @oncology_bg Hey Vinay. Still waiting on your response to the part in the @bmj_latest opinion piece that benefits of lung cancer screening (to avert over 12,000 lung cancer deaths) "must be set against 27,034 major complications". #lcsm
Brendon Stiles @BrendonStilesMD
@VPrasadMDMPH @MarilynNelson55 @DrewMoghanaki @findlungcancer @LeciaSequist @CrisAlvaradoMD @SethBKrantz @kennylinafp @lown @AFPJournal @ShannonBrownlee @JeanneLenzer1 @chrisdraft @Pattybeatslungc @biniamkidaneMD @chrisslatore @PercyLeeMD @jillfeldman4 @JillHW @Kamacintosh @ivybelkins @aesfCEO @ellakaz @oncology_bg @bmj_latest Given your insistence on clarity, please share reference 19 which seems to be personal communication. Shouldn't we all see how you came up with the comlication numbers and matched them to the 12,000 from another reference? Let's make sure this isn't confounded data! #lcsm
JTO @JTOonline
JTO Research Watch: "Attributable Failure of First-Line Cancer Treatment and Incremental Costs Associated With Smoking by Patients With Cancer." #LCSM #LungCancer Read the full article: https://t.co/yyOKV8GMBt
Brendon Stiles @BrendonStilesMD
@VPrasadMDMPH @MarilynNelson55 @DrewMoghanaki @findlungcancer @LeciaSequist @CrisAlvaradoMD @SethBKrantz @kennylinafp @lown @AFPJournal @ShannonBrownlee @JeanneLenzer1 @chrisdraft @Pattybeatslungc @biniamkidaneMD @chrisslatore @PercyLeeMD @jillfeldman4 @JillHW @Kamacintosh @ivybelkins @aesfCEO @ellakaz @oncology_bg @bmj_latest Also helpful to know exactly how many of the 27,034 you would estimate to be the specific complications you mentioned: "lung collapse, heart attach, stroke, and death". Were these the most common or simply chosen for dramatic effect? Thanks! #lcsm
Paula @lungcancer1964
RT @AboutLungCancer: #lcsm #Lungcancerscreening saves lives, and women are almost twice as likely to die from lung cancer than breast cance…
Umberto Malapelle @UmbertoMalapel1
RT @IASLC: IASLC #SCLC19 Tweet I - The scientific community is striving to understand #SCLC – utilizing a variety of unique approaches such…
Enrique Soto @EnriqueSoto8
Judging from the results of the survey, it's going to be an uphill battle for those of us debating against written care plans @bogda_koczwara @dkmayer52 #MASCC19 There is still time to vote! @CancerCareMASCC
Christopher Steer @drcbsteer
RT @EnriqueSoto8: Judging from the results of the survey, it's going to be an uphill battle for those of us debating against written care p…
IASLC @IASLC
RT @JTOonline: JTO Research Watch: "Attributable Failure of First-Line Cancer Treatment and Incremental Costs Associated With Smoking by Pa…
ESMO - Eur. Oncology @myESMO
Five-Year Survival Data in Advanced #NSCLC Treated with Pembrolizumab https://t.co/A5FyPw9fwF #LCSM https://t.co/YvM4dyxFZU
Umberto Malapelle @UmbertoMalapel1
RT @myESMO: Five-Year Survival Data in Advanced #NSCLC Treated with Pembrolizumab https://t.co/A5FyPw9fwF #LCSM https://t.co/YvM4dyxFZU
Matthew Majzun D.O. @DrMajzun
RT @JTOonline: JTO Research Watch: "Attributable Failure of First-Line Cancer Treatment and Incremental Costs Associated With Smoking by Pa…
Lung Cancer Screening Feed @lung_ca_screen
@atstoa See my prior thread on this. https://t.co/4GR5eHtMhW
claudio baldo @baldo2_claudio
RT @StephenVLiu: #CIOT19 Final session of the day covered MDT approach in #NSCLC by #FilippoDeMarinis, #EGFR advances by #FedericoCapouzzo,…
Lung Cancer Project @LungProject
A recent @UF study revealed few doctors and high-risk patients are talking about #lungcancer screening. Learn more about benefits and risks of lung cancer screening, and why it’s important to ask your doctor if it is right for you. #lcsm: https://t.co/MZvG8Bpvcf
SITC @sitcancer
Learn about the latest FDA approved immunotherapy treatments for lung cancer, how to treat immune-related adverse events and real-world case scenarios through SITC’s free #LearnACI online course. Register today at: https://t.co/6YjsR5OliX #LCSM #LungCancer https://t.co/GlQbZxv4gB
Pasquale Pisapia @PasqualePisapia
RT @IASLC: Today is the last day to participate in our ILCN Readership Survey! Complete this 10-15 minute survey by the end of the day to…
Dr. David Tom Cooke @DavidCookeMD
RT @LungCancerFaces: “Cancer may kill my body but it will never get my spirit. I have decided, yes, decided, that I’m just not going to let…
Pasquale Pisapia @PasqualePisapia
RT @Alfdoc2: The abstract from @VanitaNoronha was the only possible practice ( if Osi not available)changing presented at #ASCO2019 . I sai…
Pasquale Pisapia @PasqualePisapia
RT @JTOonline: JTO Research Watch: "Attributable Failure of First-Line Cancer Treatment and Incremental Costs Associated With Smoking by Pa…
Christian Rolfo @ChristianRolfo
RT @JTOonline: Today, we learned that our #impactfactor for 2018 is 12.460 - up from 10.336 in 2017! The JTO now ranks 10th of all #oncolog
Silvia Ferrin @saferrin
Great !! I I rather find info scout breast cancer
JAX_CKB @JAX_CKB
#lungcancer patient with EGFR exon 19 deletion and BRAF V600E responds to the combination therapy of Dabrafenib and Osimertinib #PrecisionMedicine
Janet Freeman-Daily @JFreemanDaily
@saferrin Go for it! You’ll find more breast cancer info using the #BCSM (Breast Cancer Social Media ) hashtag rather than #LCSM (Lung Cancer Social Media).
ACCC @ACCCBuzz
ACCC’s new initiative for non-small cell #lungcancer will create and execute models for improved multidisciplinary care coordination applicable across all settings. Learn more here: #cancer #NSCLC #lcsm https://t.co/AvwLFBqs5u @accpchest @LUNGevity @IASLC @AstraZenecaUS https://t.co/OLQQgmYO10
Sylvie Bevignani @BEVIGNANI24
RT @OurWarOnCancer: Most people who r diagnosed w/ #lungcancer are NOT current smokers, or have never smoked. If U have lungs, U can get lu…
IASLC @IASLC
RT @ACCCBuzz: ACCC’s new initiative for non-small cell #lungcancer will create and execute models for improved multidisciplinary care coord…
Dr. David Tom Cooke @DavidCookeMD
RT @garyleethompson: Joining #lcsm in honor of a friend who was just diagnosed with Stage 4 #lungcancer Early 40s. Non-smoker. Still in sho…
Lung-MAP @LungMAP
RT @JFreemanDaily: T4: Oncology meetings are including more on patient experience. One poster at #ASCO19 found broadening clinical trial el…
Abdelghani Tbakhi @atbakhi
RT @Kamacintosh: Genomic Testing and Targeted Therapies May be Underused in Community Practice only 7% are test for all 7 #biomarkers, Stud…
Lung-MAP @LungMAP
RT @BrendonStilesMD: Lots of stuff happening in the RET space! #lcsm https://t.co/PF0L955kzh
Lung-MAP @LungMAP
RT @BrendonStilesMD: And as always…#LungCancer has been a hot topic! #lcsm https://t.co/Mo1ifNloqA
Lung-MAP @LungMAP
RT @JFreemanDaily: I am encouraged by progress in so many areas of #lungcancer research--different stages, different biomarkers, different…
Lung-MAP @LungMAP
RT @LungCancerEu: A summary of ASCO 2019 #lungcancer abstracts - a listing of all accepted abstracts from lung cancer track https://t.co/j…
Lung-MAP @LungMAP
RT @livinglife82: It would be great to see this become the standard for all cancers not just some. Nurse consultants play a critical role i…
Lung-MAP @LungMAP
RT @StephenVLiu: Intriguing article in the June issue of @JTOonline by #JongWooLee and @DrRoyHerbstYale tackling the impact of #KRAS on the…
Katsuaki Maehara Ph.D @KatsuakiMaehara
RT @BrendonStilesMD: Lots of stuff happening in the RET space! #lcsm https://t.co/PF0L955kzh
Katsuaki Maehara Ph.D @KatsuakiMaehara
RT @StephenVLiu: #CIOT19 Provocative discussion about the role of TMB and how to view post hoc subset analyses. Nice interchange led by @ma
Eon @eonhealth
We love connecting our community! #FF #FollowFriday @luba_greenwood @Viet_PA @BrendonStilesMD @lcsmchat @accpchest @RadiologyACR @kovacs_real @SABronchoscopy @squash5422 @HemOncWomenDocs @PhysRelations @techguy @JonathanAufray #hcldr #SoMeDocs #lcsm #hcsm #radonc #medtwitter https://t.co/6pmtUtufkV
Katsuaki Maehara Ph.D @KatsuakiMaehara
RT @APassaroMD: #CIOT19 @StephenVLiu discussing the optimal sequencing in ALK-positive #LungCancer #lcsm Improving survival optimising the…
Katsuaki Maehara Ph.D @KatsuakiMaehara
RT @StephenVLiu: #CIOT19 Debate: pembro alone (@EnriquetaFelip)or chemo/IO (@ValiPap) for PDL1 high #NSCLC - does the toxicity justify pote…
Umberto Malapelle @UmbertoMalapel1
RT @BrendonStilesMD: Lots of stuff happening in the RET space! #lcsm https://t.co/PF0L955kzh
Katsuaki Maehara Ph.D @KatsuakiMaehara
RT @Alfdoc2: The abstract from @VanitaNoronha was the only possible practice ( if Osi not available)changing presented at #ASCO2019 . I sai…
Umberto Malapelle @UmbertoMalapel1
RT @ACCCBuzz: ACCC’s new initiative for non-small cell #lungcancer will create and execute models for improved multidisciplinary care coord…
Katsuaki Maehara Ph.D @KatsuakiMaehara
RT @IASLC: IASLC member @HosseinBorghaei discusses the clinical implications of two late-breaking abstracts in #lungcancer that were presen…
Lung-MAP @LungMAP
Immunotherapies are now available in a new sub-study of @LungMAP. Over 500 hospitals and clinics in the U.S. have the trial open. To learn more, visit https://t.co/isKY5nbt0H or call 1-800-4-CANCER. We're a partn